

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	26	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances

10/562,112

NEWS 27 MAR 23 CA/CAPLUS enhanced with more than 250,000 patent
equivalents from China

NEWS 28 MAR 30 IMSPATENTS reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:17:36 ON 02 APR 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 10:17:49 ON 02 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAR 2009 HIGHEST RN 1130556-28-3

DICTIONARY FILE UPDATES: 31 MAR 2009 HIGHEST RN 1130556-28-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10562112s.str

10/562,112



```
chain nodes :
7 8 9 10 12 14 16
ring nodes :
1 2 3 4 5 6
chain bonds :
2-7 3-16 5-14 6-12 7-8 8-9 8-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-7 3-16 6-12 7-8 8-9 8-10
exact bonds :
5-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :
```

G1:H,CH3,Et,n-Pr

G2:H,CN,X

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
12:CLASS 14:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H, Me, Et, n-Pr

G2 H, CN, X

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 10:18:12 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1662971 TO ITERATE

60.1% PROCESSED 1000000 ITERATIONS

19574 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.15

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **INCOMPLETE**

PROJECTED ITERATIONS: 1662971 TO 1662971

PROJECTED ANSWERS: 32009 TO 33091

L2 19574 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

185.88

186.10

FILE 'CAPLUS' ENTERED AT 10:18:35 ON 02 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Apr 2009 VOL 150 ISS 14

FILE LAST UPDATED: 1 Apr 2009 (20090401/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

10/562,112

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2 and (bromination or cyanide or cyano)

841 L2

52260 BROMINATION

90752 CYANIDE

88926 CYANO

L3 143 L2 AND (BROMINATION OR CYANIDE OR CYANO)

=> d l3 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 143 ANSWERS - CONTINUE? Y/(N):y

13 ANSWER 3 of 143 CARLOS COFFRIGHT 2009 ACS ON STM
 ACCESSION NUMBER: 1502181774
 DOCUMENT NUMBER: 2009-123293 CARLOS
 TITLE: Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
 INVENTOR(S): Li, Xiaodong; Paton, Andrew; Tachdjian, Catherine; Xu, Meng; Li, Qing; Wang, Aileen; Suwari, Dedy; Zhang, Lian; Wang, Thomas; Barnhouse, Vincent; Amelino, Malissa; Reich, Victor; Ching, Brett; Mojum, Karamanly; Donald, S.; Reist, Paul; Ling, Jing; Shao, Wen; Priest, Chad
 SOURCE: PCT Int. Appl., 40pp.
 COUNTRY: FRANKO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009025793	A2	20090212	MO 2008-093964	20090919
US	AL, AU, AM, AO, AT, AX, AZ, BA, BB, BG, BR, CA, CB, CC, CD, CF, CG, CH, CI, CL, CN, CO, CP, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GR, GM, GU, HK, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LG, LI, LU, LV, LY, MA, MG, MK, MN, MU, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RU, SA, SD, SG, SI, SK, SL, SM, SN, SV, SW, TH, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VN, ZA, ZM, ZW			
FR	AL, AU, AM, AO, AT, AX, AZ, BA, BB, BG, BR, CA, CB, CC, CD, CF, CG, CH, CI, CL, CN, CO, CP, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GR, GM, GU, HK, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LG, LI, LU, LV, LY, MA, MG, MK, MN, MU, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RU, SA, SD, SG, SI, SK, SL, SM, SN, SV, SW, TH, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VN, ZA, ZM, ZW			
PRIORITY APPL. INFO.			US 2007-951259	P 20070921
			US 2008-471979	P 20080423

AS Specific human taste receptors (hT2R38 and hT2R34) in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. These receptors may be used in assays to identify specific compounds and assays that modulate the activation of the receptors and which may be used as additives to modify (or block) T2R-associated bitter taste in, e.g., coffee and coffee-flavored foods, beverages, and pharmaceuticals. (Chem. 12 w/ 4-N-benzyl-10-[4-methoxyphenyl]acetyl-L-histidine acid (IC50 = 0.22 mM on hT2R34 bitter receptor) reduced the bitterness of instant coffee in taste tests.)
 IT 111931-02-12
 RI, SPO (Biological study, unclassified); PFD (Food or feed use); SWM (Synthetic preparation); TSD (Therapeutic use); BMD (Biological study); PREP (Preparation); UBS (Use)
 (Human T2R taste receptor-based assays for identification of bitterness-blocking compounds.)

13 ANSWER 4 of 143 CARLOS COFFRIGHT 2009 ACS ON STM
 ACCESSION NUMBER: 2009-17976 CARLOS
 DOCUMENT NUMBER: 150214160
 TITLE: N-arylpiperidine derivatives as androgen receptor modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases
 INVENTOR(S): Sawada, Atsushi
 PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
 SOURCE: PCT Int. Appl., 22pp.
 COUNTRY: FRANKO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION: 2


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009020234	A2	20090212	WO 2008-096400	20090906
US	AL, AU, AM, AO, AT, AX, AZ, BA, BB, BG, BR, CA, CB, CC, CD, CF, CG, CH, CI, CL, CN, CO, CP, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GR, GM, GU, HK, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LG, LI, LU, LV, LY, MA, MG, MK, MN, MU, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RU, SA, SD, SG, SI, SK, SL, SM, SN, SV, SW, TH, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VN, ZA, ZM, ZW			
FR	AL, AU, AM, AO, AT, AX, AZ, BA, BB, BG, BR, CA, CB, CC, CD, CF, CG, CH, CI, CL, CN, CO, CP, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GR, GM, GU, HK, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LG, LI, LU, LV, LY, MA, MG, MK, MN, MU, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RU, SA, SD, SG, SI, SK, SL, SM, SN, SV, SW, TH, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VN, ZA, ZM, ZW			
PRIORITY APPL. INFO.			US 2008-221739	20080906
			JP 2007-205066	A 20070807
			JP 2007-299658	A 20071119

OTHER SOURCE(S): MARPAT 150:214160
 GI



AS The invention relates to N-arylpiperidine derivative of formula 1 and their salts, which are androgen receptor modulators. Comps. of formula

13 ANSWER 3 of 143 CARLOS COFFRIGHT 2009 ACS ON STM (Continued)
 88 111930-02-2 CARLOS
 CN Benzoic acid, 4-[[14-(acetylaminophenyl)methyl]11(4-methoxyphenyl)methyl]amino]methyl]- (CA INDEX NAME)



13 ANSWER 4 of 143 CARLOS COFFRIGHT 2009 ACS ON STM (Continued)
 wherein R1-R2 and R4-R6 are independently H, Me, or a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom and a group via a sulfur atom; R3 is an electron-withdrawing group; R7 is (unsubstituted alkyl) and (unsubstituted aryl); R8 is H, (unsubstituted alkyl), (unsubstituted alkenyl) and (unsubstituted cycloalkyl); R9 is a group via an oxygen atom; Ring A is (unsubstituted 5- to 6-membered ring and a spiro motif forming by a 5- to 6-membered ring with C3-4 cycloalkane and their salts thereof, are claimed. Example comp. 13 was prep. by methylation of 2-chloro-4-[(1S,3S)-2-ethyl-3-hydroxy-1-methylpiperidin-1-yl]benzonitrile. All the invention compds. were evaluated for their androgen receptor modulating activity. From the assay, it was detcd. that II exhibited an inhibition of 100 at 100 nM
 IT 1114547-34-4P, 8-[3-Chloro-4-oxano-2-fluorophenyl]acetamide
 RI, RCT (Acetamide); SWM (Synthetic preparation); PREP (Preparation); NAC (Nucleic acid or nucleoside)
 (Intermediate preparation of N-arylpiperidine derivative, as androgen receptor modulators useful in the treatment of diseases)
 88 1114547-34-4 CARLOS
 CN Acetamide, 8-[3-chloro-4-oxano-2-fluorophenyl]- (CA INDEX NAME)



1

10/562,112


L3 ANSWER 5 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009-138835 CAPLUS
 DOCUMENT NUMBER: 150168179
 TITLE: Preparation of heterocyclic compounds as nitric
 antagonists for treating urinary tract disorders,
 migraine, and gastroesophageal reflux disease
 Leonardo, Amedeo Motta, Gianni Riva, Carlo;
 INVENTOR(S):
 Proprietary
 PATENT ASSIGNER(S): Kierulff Grassano, Davide Longhi, Matteo Marz
 SOURCE: Reconditi Ireland Limited, Ire.
 PCT Int. Appl., 142pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNTRY: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 200901597	AI	20090200	MO 2008-EP4351	20090901
W: AB, AG, AL, AM, AN, AP, AT, AU, BA, BB, BC, BD, BF, BG, BH, BI, BJ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GR, GU, HK, HM, HU, IL, IN, IS, IT, JP, KE, KG, KH, KR, KZ, LA, LG, LI, LU, LV, LY, MA, MD, ME, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NE, NG, NI, NO, NZ, OM, PA, PG, PH, PI, PT, PY, RO, RU, RW, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, TH, TN, TR, TT, TZ, UA, US, UG, UZ, VC, VN, ZA, ZM, ZW				
PM: AE, AF, AR, AS, AU, BA, BB, BC, BD, BF, BG, BH, BI, BJ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GR, GU, HK, HM, HU, IL, IN, IS, IT, JP, KE, KG, KH, KR, KZ, LA, LG, LI, LU, LV, LY, MA, MD, ME, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NE, NG, NI, NO, NZ, OM, PA, PG, PH, PI, PT, PY, RO, RU, RW, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, TH, TN, TR, TT, TZ, UA, US, UG, UZ, VC, VN, ZA, ZM, ZW				
US 2009042842	AI	20090212	US 2008-185639	20090904
PRIORITY APPL. INFO.: US 2007-853677	P	20070802		


OTHER SOURCE(S): MARPAT 150168179
 01
 US 2008-451759 P 20080415

L3 ANSWER 5 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE P3 FORMAT



L3 ANSWER 5 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




AB Comps. of general formula I are claimed, wherein I is substituted prop-2-ynylidene, etc. or a 0-2, n is 0-2, Y is a linking group or is absent, R' is H or OH or is absent, R3 is H (unsubstituted) or C-alkyl, etc., and the bond between ring nodes 3 and 4 is optionally a double bond.
 I are nitric antagonists useful for the treatment of neurovascular dysfunction of the lower urinary tract, migraine and gastroesophageal reflux disease in mammals. Synthetic procedures for preparing I are exemplified. Example compound II was prepared in a multistep synthesis, culminating in the reaction of 2-aceto-6-methylpyridine and 1-[3-nitro-2-pyridinyl]-4-(prop-2-ynylidene)pyrrolidine (preparation given). In conscious rats II had an MED of 3 mg/kg or in increasing blood volume capacity.
 IT 1507418-42-7, 1-[4-Aceto-2-methylbenzyl]-4-[3-(6-methyl-2-pyridyl)-2-propenylidene]pyrrolidine
 R3: PAC (Pharmacological activity); RPN (Synthetic preparation); TRU (Therapeutic use); NIG (Biological study); PPM (Preparation); USES (Uses)
 Group candidate preparation of heterocyclic combs. as nitric antagonists for treating urinary tract disorders, migraine, and gastroesophageal reflux disease
 BR 1507418-42-7 CAPLUS
 CN Acetanilide
 N-[2-methyl-4-[4-[2-(6-methyl-2-pyridyl)-2-propenyl-1-ylidene]-1-pyridinyl]carboxyl]phenyl) (CA INDEX NAME)

L3 ANSWER 6 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009-55648 CAPLUS
 DOCUMENT NUMBER: 150144195
 TITLE: Preparation of tropane derivatives useful as pesticides
 INVENTOR(S): Salinas, Patricia; Clarke, Eric Daniels; Elliott, Alison
 SOURCE: Clara; Fawc, Delphine; Huster, Ottmar Franz;
 Mueller, Ugo; Renold, Peter; Targett, Sacha; Whittingham, William Guy
 PATENT ASSIGNER(S): Syngenta Participations A.-G., Swiss; Syngenta Limited
 PCT Int. Appl., 143pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2009070115	AI	20090115	MO 2008-EP5633	20090710
W: AB, AG, AL, AM, AN, AP, AT, AU, BA, BB, BC, BD, BF, BG, BH, BI, BJ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GR, GU, HK, HM, HU, IL, IN, IS, IT, JP, KE, KG, KH, KR, KZ, LA, LG, LI, LU, LV, LY, MA, MD, ME, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NE, NG, NI, NO, NZ, OM, PA, PG, PH, PI, PT, PY, RO, RU, RW, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, TH, TN, TR, TT, TZ, UA, US, UG, UZ, VC, VN, ZA, ZM, ZW				
PM: AE, AF, AR, AS, AU, BA, BB, BC, BD, BF, BG, BH, BI, BJ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GR, GU, HK, HM, HU, IL, IN, IS, IT, JP, KE, KG, KH, KR, KZ, LA, LG, LI, LU, LV, LY, MA, MD, ME, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NE, NG, NI, NO, NZ, OM, PA, PG, PH, PI, PT, PY, RO, RU, RW, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, TH, TN, TR, TT, TZ, UA, US, UG, UZ, VC, VN, ZA, ZM, ZW				
US 2009070115	AI	20090115	US 2008-13602	20090710
PRIORITY APPL. INFO.: US 2007-13602	A	20070712		

OTHER SOURCE(S): MARPAT 150144195
 01



AB The title combs. I [R1 = (un)substituted mono- or bicyclic ring system containing 5-10 ring atoms (at least one of them being H atom); R2, R3 = H, OH, alkyl, etc., or R2 and R3, together with the carbon atom to which they are attached, form (un)substituted 5-7 membered oxygen containing ring] or R3


L3 ANNEX 8 of 143 CAPLUS COFFRIGHT 2009 ACS on STN (Continued)
 ANGIOGENESIS, aryl, etc., R4 is H, F, alkyl, or stereoisomer,
 tautomer, pharmacologically-acceptable salts, or prodrugs, which are
 inhibitors of factor XIIa and/or plasma kallikrein, *in vivo*, *in vitro*, and
 methods of using them, e.g., for the treatment or prophylaxis of
 thrombotic diseases. Thus, dipeptide I was used, by a suitable
 sequence

using reactants Boc-protected phenylalanine, R2 (4-aminophenyl)acetate,
 Me (dimethylphosphoryl)acetate, and 5-chloro-2-tetrazol-1-ylbenzylaldehyde,
 and showed K_i = 139.7 nM for inhibition of factor XIIa.

IT 1094102-77-10
 R4: PAC (Pharmacological activity); SPN (Synthetic preparation); TSP
 (Therapeutic use); R2C (Biological study); PREP (Preparation); USES
 (Uses)

Preparation of dipeptide analogs as coagulation factor inhibitors)
 CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANNEX 8 of 143 CAPLUS COFFRIGHT 2009 ACS on STN (Continued)
 ANGIOGENESIS, aryl, etc., R4 is H, F, alkyl, or stereoisomer,
 tautomer, pharmacologically-acceptable salts, or prodrugs, which are
 inhibitors of factor XIIa and/or plasma kallikrein, *in vivo*, *in vitro*, and
 methods of using them, e.g., for the treatment or prophylaxis of
 thrombotic diseases. Thus, dipeptide I was used, by a suitable
 sequence

using reactants Boc-protected phenylalanine, R2 (4-aminophenyl)acetate,
 Me (dimethylphosphoryl)acetate, and 5-chloro-2-tetrazol-1-ylbenzylaldehyde,
 and showed K_i = 139.7 nM for inhibition of factor XIIa.

IT 1094102-77-10
 R4: PAC (Pharmacological activity); SPN (Synthetic preparation); TSP
 (Therapeutic use); R2C (Biological study); PREP (Preparation); USES
 (Uses)

Preparation of dipeptide analogs as coagulation factor inhibitors)
 CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

Preparation of dipeptide analogs as coagulation factor inhibitors)

CH Benzenepropanamide, 2-[[4-(acetylamino)phenyl]methyl]-N-[12-[5-chloro-
 2-(2-tetrazol-1-yl)phenyl]ethyl]-, (4S)- (CA INDEX NAME)

13 ANSWER 14 OF 143 CAPULUS COPYRIGHT 2009 ACS ON STM
 ACCESSION NUMBER: 20091448429 CAPULUS
 DOCUMENT NUMBER: 1501962
 TITLE: Preparation of pyrazolidinones as Casin kinase II
 (CHEM)


INVENTOR(S): Kollner, Klaus P.; Kearney, Patrick; Ray, Manoj;
 Aronow, Arlyn Chan, Wei; Ji, Vicky; Cortez, Jeffrey;
 Kimmy, Du, Hongyong; Huang, Ping; Kame, Brian; Kim,
 Moon Beom; Chang, Michael; Teshko, Amy L.; No, Mo;
 Sabaria, Christian A.; Zhou, Peiwen

PATENT ASSIGNEE(S): Eukaline, Inc., USA
 SOURCE: PCT Int. Appl., Supp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACQ. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
NO 2008143759	AL	20081127	WO 2008-054139	20080424	
Wt	AS, AG, AL, AM, AO, AT, AU, BE, BR, BS, BY, BG, BM, BT, BS, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GH, GR, GU, HK, HU, IL, IN, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, ME, MG, MN, MU, MW, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PT, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV, SZ, TD, TH, TN, TT, UA, US, UZ, VC, VN, ZA, ZM, ZW	MM	AD, AE, AG, AR, AU, BA, BB, BE, BF, BG, BH, BR, BS, BT, BY, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GH, GR, GU, HK, HU, IL, IN, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, ME, MG, MN, MU, MW, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PT, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV, SZ, TD, TH, TN, TT, UA, US, UZ, VC, VN, ZA, ZM, ZW	US 2007-826159	P 20070425

PROB217 AFFIL. INFO.:
 OTHER SOURCE(S): MANSAT 15015762
 CI



13 ANSWER 13 OF 143 CAPULUS COPYRIGHT 2009 ACS ON STM
 ACCESSION NUMBER: 2009136999 CAPULUS
 DOCUMENT NUMBER: 149156614
 TITLE: Preparation of pyrazolidinones as p38 MAP kinase
 inhibitors which lower plasma concentrations of
 TNF- α , IL-1 β , IL-6, and/or IL-8
 INVENTOR(S): Pettus, Liping R.; Zakker, Andrew Xu, Shimin; Wurz,
 Ryan
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 111pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACQ. NUM. COUNT: 2
 PATENT INFORMATION: 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
NO 2008137176	AL	20081018	WO 2008-058565	20080506	
Wt	AS, AG, AL, AM, AO, AT, AU, BE, BR, BS, BY, BG, BM, BT, BS, CA, CH, CN, CO, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GH, GR, GU, HK, HU, IL, IN, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, ME, MG, MN, MU, MW, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PT, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV, SZ, TD, TH, TN, TT, UA, US, UZ, VC, VN, ZA, ZM, ZW	MM	AD, AE, AG, AR, AU, BA, BB, BE, BF, BG, BH, BR, BS, BT, BY, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GH, GR, GU, HK, HU, IL, IN, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, ME, MG, MN, MU, MW, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PT, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV, SZ, TD, TH, TN, TT, UA, US, UZ, VC, VN, ZA, ZM, ZW	US 2008-151478	20080506

PROB217 AFFIL. INFO.:
 OTHER SOURCE(S): MANSAT 149156614
 CI




AS Title compds. [7] A1-A4 = CH₃, R₂ s2 of A1-A4 = R₂ = O, S, NCH₃,
 R1 = R, (substituted) H-, O-, S-containing alkyl, alkenyl, alkynyl,
 cycloalkyl, cycloalkenyl, heterocycloalkyl, R₂, R3 = H, halo, haloalkyl, NO₂,
 cyano, (substituted) H-, O-, S-containing alkyl, alkenyl, alkynyl,
 cycloalkyl, cycloalkenyl; R4 = cyano, CONH₂, (substituted) H-,

13 ANSWER 14 OF 143 CAPULUS COPYRIGHT 2009 ACS ON STM (Continued)

AR The title compds. 1 R = O or S; R1 = (unsubstituted aryl; R2 =
 (unsubstituted heterocycloalkyl, heterocycloalkyl, indolyl, etc.; R3 = H, or
 R1 and R3 can join to form a ring of 5-6 carbon atoms or R1 = aryl and
 R2 = (unsubstituted indolyl)) which are inhibitors of Casin kinase II
 (CK2) pathways, were prepared 5-6-, a multi-step synthesis of 17,
 starting from 1-(2-hydroxyphenyl)ethanone and 1-bromo-2-methylpropane, was given.
 Exemplified compds. 1 have been tested for their CK2 inhibitory activity
 and showed IC₅₀ values of less than 5000 nM. Pharmacological comparison
 comparing the compound 1 is also disclosed.

17 108426-85-8P
 R1a RCT (Reagent); STM (Synthetic preparation); PREP (Preparation); NACT
 (Reagent or reagent)
 Preparation of pyrazolidinone compds. as Casin kinase II inhibitors
 for treating and preventing disease)


NO 106426-85-8 CAPULUS
 CI Anelamide, N-[2-ethyl-4-[3-[2-[2-methoxyethoxy]phenyl]-1,3-
 dioxo]propyl]phenyl]- (CA INDEX NAME)




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

13 ANSWER 13 OF 143 CAPULUS COPYRIGHT 2009 ACS ON STM (Continued)
 R1 = S-containing alkyl, alkenyl, alkynyl, cycloalkyl; R2 = S-, NH₂,
 CONH₂, OH, CH₃, CONH₂, etc.; R3 = H, halo, haloalkyl, NO₂,
 cyano, CONH₂, NH₂, (substituted) H-, O-, S-containing alkyl; R4 = H,
 (substituted) H-, O-, S-containing alkyl, alkenyl, alkynyl, cycloalkyl,
 cycloalkenyl), were prep. Thus,
 2-[11-(5,6-difluorophenyl)-7-methyl-4-oxo-
 4,7-dihydro-1H-pyrazolo[3,4-b]pyridin-5-yl]-3-fluoro-4-methylbenzamide
 (prep. outlined) inhibited p38 with IC₅₀ = 1 nM.
 17 108572-82-8 108572-92-5P 108572-96-8P
 R1a RCT (Pharmacological activity); PREP (Prophetic); STM (Synthetic
 preparation); THO (Therapeutic use); BIO (Biological study); PREP
 (Preparation); USE (Use)
 Preparation of pyrazolidinones as p38 MAP kinase inhibitors

NO 108572-82-4 CAPULUS
 CI Butanamide,
 N-[11-[2-[2-(dimethylamino)ethyl]-4,7-dihydro-6-oxo-7-propyl-1H-
 pyrazolo[3,4-b]pyridin-5-yl]-4-methylphenyl]- (CA INDEX NAME)



NO 108572-93-5 CAPULUS
 CI Butanamide, N-[11-[7-ethyl-4,7-dihydro-1-(3-hydroxy-1-pyrrolidinyl)-6-oxo-
 18-pyrazolo[3,4-b]pyridin-5-yl]-4-methylphenyl]- (CA INDEX NAME)



NO 108572-94-8 CAPULUS
 CI Butanamide,
 N-[11-(1,7-dimethyl-4,7-dihydro-4-oxo-18-pyrazolo[3,4-b]pyridin-
 5-yl)-4-methylphenyl]- (CA INDEX NAME)

AS The title comp., (I) or salts thereof [Al, A2, A3 = C, N; ring G = benzene, furan, or thiophene; ring, G-membered aromatic heterocyclic ring containing N, 5-membered aromatic heterocyclic ring containing N]

Zheteroatoms selected from O, S and N; W = C, Si; X = halo, cyano, NO₂, N₃, thiocyanato, substituted saturated heterocyclic, each (un)substituted HO, HNR₂, Cl-alkyl, C3-8 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, or Ph, etc.; Y = halo, cyano, NO₂, N₃, thiocyanato, substituted saturated heterocyclic, each (un)substituted HO, HNR₂, Cl-alkyl, C3-8 cycloalkyl, C2-6 alkenyl, or Ph, etc.; R1 = each (un)substituted CH=CH, Ph, CONH₂, C(S)NR₂, 4,5-dihydroimidazol-3-yl, or 5,4-dihydro-1H-1,2-oxiazol-3-yl, etc.; R2, R3 = C2-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or Ph, etc.


L3 ANSWER 29 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 not Me or ethyl], and their pharmaceutically acceptable salts, are prepd.
 Thus, e.g., it was prepd. by dipeptide reaction of
 2-hydroxy-3-oxo-1-pyrrolidine-3-carboxylic acid tert-Bu ester [prepa.
 given] with 3,4-dichlorophenylmagnesium bromide, followed by oxidation and
 deprotection were found to have affinity for human serotonin
 transporter (SERT) in scintillation proximity assay (SPA), e.g.,
 naphthalen-2-yl(3-propylpyrrolidin-3-yl)methanone exhibited a $K_{1/2}$ of
 approx. 8.82 nM in this assay. 1 should prove useful for the treatment of
 diseases associated with monoamine reuptake inhibitors such as depression
 and anxiety.
 IT 1013811-29-02, N-[2-Chloro-4-[(3-propylpyrrolidin-3-
 yl)oxycarbonyl]phenyl]acetamide
 EIA PAC (Pharmacological activity); SPN (Synthetic preparation); TBS
 (Toxicologic use); BIOG (Biological study); PREP (Preparation); USES
 (Uses)
 [Preparation of pyrrolidinyl and piperidinyl ketone deriva. for
 treatment of diseases associated with monoamine reuptake inhibitors]
 MN 1013811-29-0 CAPIUS
 CN Acetanilide, N-[2-chloro-4-[(3-propyl-3-pyrrolidinyl)oxycarbonyl]phenyl]- (CA
 INDEX NAME)



L3 ANSWER 29 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009167645 CAPLUS
 DOCUMENT NUMBER: 1491146
 TITLE: Preparation of pyridine derivatives as insecticides
 INVENTOR(S): Reuninger, Delphine; Pohl, Michael; Parra Lapido,
 Liliana; Kaye, Michael; Kohn, David G.; Colburn,
 Deborah L.; Anagnostou, Douglas D.
 SOURCE: PCT Int. Appl., 117pp.
 CIBISI P3242
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY NO., NUM. COMM.: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006051465	A1	20060405	WO 2007/043341	20071118
W1	AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ			

PRIORITY APPL. INT.: 1
 OTHER SOURCE(S): NAUAPT 1491346
 CI




AB The pyridine deriva. I [A = bond or (un)substituted CH2; X = bond or (un)substituted C(3-alkyl)enyl; R1, R2 = H, halo, cyano, alkyl, haloalkyl, etc.; R3 = H, halo or alkyl; R4 = H or alkyl; R5 = halo, CH, cyano or haloalkyl; R6 = alkyl, alkylenyl or alkynyl; n = 0 or 1; n = 0, 1 or 2] are prepared as insecticides.
 IT 1013936-32-02
 NLA AGR (Agricultural use); PREP (Preparation); SPN (Synthetic preparation);
 BIOG (Biological study); PREP (Preparation); USES (Uses)
 [Preparation as insecticide]

L3 ANSWER 29 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 IT 1013936-32-02 CAPIUS
 CN INDEX NAME NOT YET ASSIGNED
 Absolute stereochemistry.



IT 1013936-32-02
 NLA AGR (Agricultural use); SPN (Synthetic preparation); BIOG (Biological study); PREP (Preparation); USES (Uses)
 [Preparation as insecticide]
 MN 1013936-32-0 CAPIUS
 CN Acetanilide, N-[4-[[[(2S)-2-[[[(5-chloro-3-pyridinyl)oxy]methyl]-1-acetindyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



MN 1013936-32-0 CAPIUS
 CN Acetanilide, N-[4-[[[(2S)-2-[[[(5-chloro-3-pyridinyl)oxy]methyl]-1-acetindyl]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




MN 1013936-32-0 CAPIUS
 CN Acetanilide, N-[4-[[[(2S)-2-[[[(5-chloro-3-pyridinyl)oxy]methyl]-1-acetindyl]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4
 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RS
 FORMAT

1,3 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




NO 1022966-14-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




NO 1022966-15-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

1,3 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




NO 1022966-34-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




NO 1022966-35-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

1,3 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




NO 1022966-34-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




NO 1022966-35-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

1,3 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




NO 1022967-71-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




NO 1022967-72-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

1,3 ARSNER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RI 1022987-91-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RI 1022987-92-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

1,3 ARSNER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RI 1022988-21-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RI 1022988-22-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

1,3 ARSNER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RI 1022987-92-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RI 1022987-94-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

1,3 ARSNER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RI 1022988-21-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RI 1022988-22-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

1,3 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




BN 1022988-11-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




BN 1022988-12-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

1,3 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




BN 1022988-43-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




BN 1022988-44-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

1,3 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




BN 1022988-13-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




BN 1022988-54-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

1,3 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




BN 1022988-64-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




BN 1022988-67-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

13 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



NN 1022987-17-0 CAPLUS

CN 18-Pyrazole-4-carboxamide, 1-acetyl-3,5-dimethyl-N-[3-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl)phenyl]-N-(1-oisopropyl)- (CA INDEX NAME)




NN 1022987-16-1 CAPLUS

CN 18-Pyrazole-4-carboxamide, N-acetyl-3,5-dimethyl-N-[3-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl)phenyl]-N-(1-oisopropyl)- (CA INDEX NAME)


13 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)

[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]-1-(1-oisobutyl)- (CA INDEX NAME)



NN 1022987-21-4 CAPLUS


CN 18-Pyrazole-4-carboxamide, 3,5-dimethyl-N-[3-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl)phenyl]-N-(1-oisobutyl)-N-(1-oisopropyl)- (CA INDEX NAME)



NN 1022987-36-5 CAPLUS


CN 18-Pyrazole-4-carboxamide, N-acetyl-1-(cyclopropylcarbonyl)-3,5-dimethyl-N-

13 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



NN 1022987-17-2 CAPLUS

CN 18-Pyrazole-4-carboxamide, 3,5-dimethyl-N-[3-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl)phenyl]-N-(1-oisobutyl)-N-(1-oisopropyl)- (CA INDEX NAME)



NN 1022987-24-3 CAPLUS

CN 18-Pyrazole-4-carboxamide, N-acetyl-3,5-dimethyl-N-[3-(2-methylpropyl)-4-


13 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)

[3-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl)phenyl]-N-(1-oisobutyl)-N-(1-oisopropyl)- (CA INDEX NAME)



NN 1022987-37-6 CAPLUS


CN 18-Pyrazole-4-carboxamide, 1-(cyclopropylcarbonyl)-3,5-dimethyl-N-[3-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl)phenyl]-N-(1-oisobutyl)-N-(1-oisopropyl)- (CA INDEX NAME)




NN 1022987-44-7 CAPLUS

CN 18-Pyrazole-4-carboxamide, N-acetyl-1-(2,2-dimethyl-1-oisopropyl)-3,5-dimethyl-N-[3-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl)phenyl]-N-(1-oisobutyl)-N-(1-oisopropyl)- (CA INDEX NAME)

13 ABSTRACT 35 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RI 1022987-47-8 CAPLUS
 CN 18-Pyrazole-4-carboxamide,
 N-(2,4-dimethyl-1-oxo-1H-pyridin-3-yl)-
 2,2-trifluoro-1-methoxy-1-(trifluoromethyl)-
 ethylphenyl]-N-(1-oxopropyl)- (CA INDEX NAME)




RI 1022989-13-0 CAPLUS

13 ABSTRACT 35 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RI 1022989-18-1 CAPLUS
 CN 18-Pyrazole-4-carboxamide,
 N-(2,4-dimethyl-1-oxo-1H-pyridin-3-yl)-
 2,2-trifluoro-1-methoxy-1-(trifluoromethyl)-
 ethylphenyl]-N-(1-oxopropyl)- (CA INDEX NAME)




RI 1022989-28-2 CAPLUS
 CN 18-Pyrazole-4-carboxamide,
 N-(2,4-dimethyl-1-oxo-1H-pyridin-3-yl)-
 2,2-trifluoro-1-methoxy-1-(trifluoromethyl)-
 ethylphenyl]-N-(1-oxopropyl)- (CA INDEX NAME)

13 ABSTRACT 35 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 CN 18-Pyrazole-4-carboxamide, 3,5-dimethyl-N-(3-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethylphenyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethylphenyl)-N-(1-oxopropyl)- (CA INDEX NAME)




RI 1022989-27-0 CAPLUS
 CN 18-Pyrazole-4-carboxamide, N-(2,4-dimethyl-1-oxo-1H-pyridin-3-yl)-
 2,2-trifluoro-1-methoxy-1-(trifluoromethyl)-ethylphenyl]-N-(1-oxopropyl)- (CA INDEX NAME)

13 ABSTRACT 35 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RI 1022989-30-5 CAPLUS
 CN 18-Pyrazole-4-carboxamide, 3,5-dimethyl-N-(3-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethylphenyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethylphenyl)-N-(1-oxopropyl)- (CA INDEX NAME)



RI 1022989-31-6 CAPLUS
 CN 18-Pyrazole-4-carboxamide, 3,5-dimethyl-N-(3-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethylphenyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethylphenyl)-N-(1-oxopropyl)- (CA INDEX NAME)

13 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RI 1022989-12-7 CAPLUS
 CN 18-Pyrazole-4-carboxamide, 1-(cyclobutylcarbonyl)-3,5-dimethyl-N-[2-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoroethyl)ethyl)phenyl]-N-(1-oxoethyl)- (CA INDEX NAME)




RI 1022989-13-8 CAPLUS
 CN 18-Pyrazole-4-carboxamide, 1-acetyl-3,5-dimethyl-N-[2-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoroethyl)ethyl)phenyl]-N-(1-oxoethyl)- (CA INDEX NAME)

13 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RI 1022989-16-1 CAPLUS
 CN 18-Pyrazole-4-carboxamide, 3,5-dimethyl-N-[2-(2-methyl-1-oxoethyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoroethyl)ethyl)phenyl]-N-(1-oxoethyl)- (CA INDEX NAME)




RI 1022989-17-2 CAPLUS
 CN 18-Pyrazole-4-carboxamide, 1-(2,2,2-trifluoro-1-oxoethyl)-3,5-dimethyl-N-[2-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoroethyl)ethyl)phenyl]-N-(1-oxoethyl)- (CA INDEX NAME)

13 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RI 1022989-14-9 CAPLUS
 CN 18-Pyrazole-4-carboxamide, 3,5-dimethyl-N-[2-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoroethyl)ethyl)phenyl]-N-(1-oxoethyl)- (CA INDEX NAME)




RI 1022989-15-0 CAPLUS
 CN 18-Pyrazole-4-carboxamide, 3,5-dimethyl-N-[2-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoroethyl)ethyl)phenyl]-N-(1-oxoethyl)- (CA INDEX NAME)

13 ANSWER 35 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RI 1022989-18-3 CAPLUS
 CN 18-Pyrazole-4-carboxamide, 1-(cyclopropylcarbonyl)-3,5-dimethyl-N-[2-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoroethyl)ethyl)phenyl]-N-(1-oxoethyl)- (CA INDEX NAME)




RI 1022989-19-4 CAPLUS
 CN 18-Pyrazole-4-carboxamide, 1-(cyclobutylcarbonyl)-3,5-dimethyl-N-[2-(2-methylpropyl)-4-(2,2,2-trifluoro-1-methoxy-1-(trifluoroethyl)ethyl)phenyl]-N-(1-oxoethyl)- (CA INDEX NAME)

13 ANSWER 37 of 143 CAPLUS COPYRIGHT 2009 ACS on STM
 ACCESSION NUMBER: 2009153923 CAPLUS
 DOCUMENT NUMBER: 148497702
 TITLE: Disperser also dyes for printing on and dyeing hydrophobic substrates
 INVENTOR(S): Jordan, Bartelme Neubauer, Stefan
 PATENT ASSIGNOR(S): DyStar Textilfarben GmbH & Co. Deutschland KG
 SOURCE: Ger. Offen., 23pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNTRY: Germany
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004005642	A1	20040430	DE 2006-102004005642	20061027
NO 2004049716	A3	20040922	NO 2007-024202	20071016
Wt, At, AG, AU, AM, AT, AU, AG, BA, BB, BG, BE, BR, BY, BS, CA, CH, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LB, LU, LV, LT, LU, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, SM, SV, TH, TR, UA, US, UZ, UZ, VC, VE, ZA, ZM, ZW				
RM, AT, BG, BR, CA, CH, CN, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LB, LU, LV, LT, LU, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, SM, SV, TH, TR, UA, US, UZ, UZ, VC, VE, ZA, ZM, ZW				
RM, AT, BG, BR, CA, CH, CN, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LB, LU, LV, LT, LU, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, SM, SV, TH, TR, UA, US, UZ, UZ, VC, VE, ZA, ZM, ZW				
RM, AT, BG, BR, CA, CH, CN, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LB, LU, LV, LT, LU, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, SM, SV, TH, TR, UA, US, UZ, UZ, VC, VE, ZA, ZM, ZW				

PRIORITY APPL. INFO.: DE 2006-102004005642A 20061027

OTHER SOURCE(S): MANDAT 148:49700
 G2



AB 2-Oxoalkyl esters, especially 2-oxopropyl esters of deriv. phenylazo acid such as 1 are used for dyeing hydrophobic substrates and for jet printing inks for textile printing. A typical ink composition containing 5.34 1, 2.54


13 ANSWER 38 of 143 CAPLUS COPYRIGHT 2009 ACS on STM
 ACCESSION NUMBER: 2009150394 CAPLUS
 DOCUMENT NUMBER: 148495951
 TITLE: Arylamide and related compounds as DGAT1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases
 INVENTOR(S): Glinzner, Thomas A.
 PATENT ASSIGNOR(S): Novartis A.G., Switz.
 SOURCE: PCT Int. Appl., 24pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 2004048991	A3	20040424	NO 2007-0081607	20071017
NO 2004048991	A3	20040710		
Wt, At, AG, AU, AM, AT, AU, AG, BA, BB, BG, BE, BR, BY, BS, CA, CH, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LB, LU, LV, LT, LU, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, SM, SV, TH, TR, UA, US, UZ, UZ, VC, VE, ZA, ZM, ZW				
RM, AT, BG, BR, CA, CH, CN, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LB, LU, LV, LT, LU, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, SM, SV, TH, TR, UA, US, UZ, UZ, VC, VE, ZA, ZM, ZW				
RM, AT, BG, BR, CA, CH, CN, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LB, LU, LV, LT, LU, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, SM, SV, TH, TR, UA, US, UZ, UZ, VC, VE, ZA, ZM, ZW				
RM, AT, BG, BR, CA, CH, CN, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LB, LU, LV, LT, LU, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, SM, SV, TH, TR, UA, US, UZ, UZ, VC, VE, ZA, ZM, ZW				

PRIORITY APPL. INFO.: US 2006-039909 P 20061018

OTHER SOURCE(S): MANDAT 148:495951
 G2

A-L1-B-C-D 1



AB The invention provides compds. of the following structure of formula 1 that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans. Compds. of formula 1

wherein A is (un)substituted alkyl, (un)substituted alkoxy, (un)substituted cycloalkyl, (un)substituted aryl, and (un)substituted

13 ANSWER 37 of 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 dispersing agent (Disperbyk 190), 20R 1,5-pentandiol, M diethylene glycol monomethyl ether, 0.018 a biocide and 50-998 water can be used for jet-printing on a pre-treated polyester substrate followed by fixing during 7 min at 175°
 17 1021394-44-EP 1021394-55-7P 1021394-56-EP
 RU IMF (Industrial manufacturer); PREP (Preparation); PREP (Preparation) (disperse also dyes for printing on and dyeing hydrophobic substrates)
 RU 1021394-54-8 CAPLUS
 RU β -Alanine, N-[1-(acetamidino)-4-[(2-[4-(4-dinitrophenyl)diacetyl]-2-methylphenyl]-2-oxopropyl ester (CA INDEX NAME)



RU 1021394-55-7 CAPLUS
 β -Alanine, N-[1-(acetamidino)-4-[(2-[4-(4-dinitrophenyl)diacetyl]-2-methylphenyl]-2-oxopropyl ester (CA INDEX NAME)



RU 1021394-56-8 CAPLUS
 β -Alanine, N-[1-(acetamidino)-4-[(2-[4-(4-dinitrophenyl)diacetyl]-2-methylphenyl]-2-oxopropyl ester (CA INDEX NAME)



13 ANSWER 38 of 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 heterocyclically, 11 is substituted amine, thioamide, amide, sulfonamide, carbamate, and urea; R is (un)substituted divalent heterocyclically (un)substituted phenyl) D or H, halo, CN, CH, alkanoylamino, carbonyl, carbamoyl, etc., and their pharmaceutically acceptable salts, and prodrugs thereof, are claimed. Example compd. 11 was prep'd by acylation of 4-nitrobenzene-1,3-diamine with Et chloroformate, the resulting (7-amino-(4-nitrophenyl)carbamate acid Et ester underwent hydrolytation to give (7,4-diaminophenyl)carbamate acid Et ester dihydrochloride, which underwent cyclization with 2-chloromethylacetate to give compd. 11. All the invention compounds were evaluated for their DGAT1 inhibitory activity (some data given)
 17 1021165-59-CP
 RU ACT (Reactant); RSM (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Intermediate; preparation of arylamides and related compds. as DGAT1 inhibitors useful in the treatment of diseases)
 RU 1021165-59-2 CAPLUS
 CN Antamide, N-(4-formyl-3,5-dimethylphenyl) (CA INDEX NAME)




13 ANSWER 40 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM
 ACCESSION NUMBER: 2009:472036 CAPLUS
 DOCUMENT NUMBER: 14847870
 TITLE: Preparation of pyridinecarboxanilide derivatives as agricultural or horticultural agents
 INVENTOR(S): Furuya, Takashi; Hamo, Hisao; Sato, Akiyuki;
 Yasokawa, Noriaki; Fujioha, Shinobu;
 Shibata, Masahiko Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 65pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY AND HUM. COUNTRY: Japan
 PATENT INFORMATION: 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008044712	A1	20080417	WO 2007-098719	20071010
US	AS, AG, AD, AM, AT, AU, AZ, BA, BB, BG, BR, BS, BY, BE, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GB, GR, HK, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LA, LV, LY, MA, MD, ME, MG, MK, MN, MU, MV, MW, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SV, SY, TH, TJ, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RU	AS, AG, AD, AM, AT, AU, AZ, BA, BB, BG, BR, BS, BY, BE, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GB, GR, HK, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LA, LV, LY, MA, MD, ME, MG, MK, MN, MU, MV, MW, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SV, SY, TH, TJ, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
JP	AS, AG, AD, AM, AT, AU, AZ, BA, BB, BG, BR, BS, BY, BE, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GB, GR, HK, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LA, LV, LY, MA, MD, ME, MG, MK, MN, MU, MV, MW, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SV, SY, TH, TJ, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			

PRIORITY APPL. INFO: JPNPAT 148:47870
 OTHER SOURCE(S):
 GI: NALPAT 148:47870


13 ANSWER 40 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)




RU 1019199-15-3 CAPLUS
 CN 3-Pyridinecarboxanilide, N-acetyl-2-methyl-N-[2-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]-8-(1-oxopropyl)- (CA INDEX NAME)



RU 1019199-16-4 CAPLUS
 CN 3-Pyridinecarboxanilide, 2-methyl-N-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]-8-(1-oxopropyl)- (CA INDEX NAME)





RU 1019199-17-5 CAPLUS
 CN 3-Pyridinecarboxanilide, 2-methyl-N-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]-8-(1-oxopropyl)- (CA INDEX NAME)



RU 1019199-17-3 CAPLUS
 CN 3-Pyridinecarboxanilide, 2-bromo-N-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-


13 ANSWER 40 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)




AB Title compds. 1 (R1 = H, alkyl, haloalkyl, etc.; R2 = H, halo, alkyl, etc.; R3 = alkyl, haloalkyl, allyl, etc.; Z = cyano or sulfur atom; n = 0-3; X = halo, cyano, nitro, etc.; n = 0-4; Y = halo, cyano, nitro, etc.) or salts thereof were prepared for example, 2-chloro-1-methylpyridinium iodide mediated condensation of 3-methyl-3-pyridinecarboxylic acid with 3-isobutyl-4-(1-methoxy-2,2,2-trifluoro-1-(trifluoromethyl)ethyl)aniline afforded compound 11. The amplified compound 11 controlled Tetrahymena urticae by 100% at 50 ppm.
 IT 1019199-44-OP 1019199-55-3P 1019199-56-4P
 1019199-17-3P 1019199-17-3P 1019199-17-3P
 RU: AGS (Agricultural use); RSP (Biological study, unclassified); SPH (Synthetic preparation); RSC (Biological study); PREP (Preparation);

USES
 (Uses)
 (Preparation of pyridinecarboxanilide deriv. as agricultural or horticultural agents)
 RU 1019199-44-0 CAPLUS
 CN 3-Pyridinecarboxanilide,
 N-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]-8-(1-oxopropyl)- (CA INDEX NAME)

13 ANSWER 40 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)



RU 1019199-49-3 CAPLUS
 CN 3-Pyridinecarboxanilide, 2-bromo-N-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]-8-(1-oxopropyl)- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE IE

FORMAT

L3 ANMER 41 OF 143 CAPUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 2009148805 CAPUS
 DOCUMENT NUMBER: 148172558
 TITLE: Preparation of triazolinopyridazine derivatives as
 xanthine oxidase inhibitors and pharmaceuticals
 containing them for treatment of gout, inflammation,
 ischemia-reperfusion injury, etc.
 INVENTOR(S): Nagashima, Shizuo; Kameda, Shinichi; Naito, Junichiro;
 Inoue, Takayuki; Ono, Atsushi; Nagata, Goro;
 Ashikawa,
 Naoki; Matsumoto, Koji
 PATENT ASSIGNEE(S): Fuji Takasho Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, Jppo.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1
 PATENT NO. _____ DATE _____
 KIND _____ APPLICATION NO. _____
 JP 2006098107 A 20060917 JP 2006-270450 20061002
 PRIORITY APPL. INFO.: JP 2006-270450 20061002
 OTHER SOURCE(S): MARPAT 148472058
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AS Pharmaceuticals containing title deriva. I [X = substituted Ph II,
 substituted
 pyridyl; R1 = cyano, NO2, halo, CF3; R2, R3 = halo, NO2,
 lower cycloalkyl, haloalkyl, aryl, carbonyl, haloalkoxy, lower alkyl,
 lower
 alkyl-(un)substituted piperazyl, etc.], their pharmaceutically-acceptable
 salts, or their hydrates are used as prophylactic and/or therapeutic
 drugs for hyperuricemia, gout, inflammatory diseases, competitive heart
 failure, ischemia-reperfusion injury, cancer, nerve disease, etc. A
 IMHO
 solution of X 2,4-diarylampholate, prepared by heating 4-OZMNAH and
 KCN in
 IMHO, was treated with H2SO4/CH2OH2, at room temperature to give 3-cyano
 4-[2-methoxyethoxy]phenonitrile, 500 mg of which was treated with MeCN
 in MeOH at room temperature for 18 h and further treated with
 pyridine-4-carboxyl acid hydrazide under reflux for 19 h to give 290
 mg 4-[3-(3-cyano-4-[2-methoxyethoxy]phenyl)-1,2,4-triazol-3-
 yl]pyridazine (IV). Thus, 2050 of IV against bovine milk xanthine
 oxidase
 was 2.1 mM. Oral administration of IV to mice lowered plasma uric acid
 concentration
 IT 1020043-39-5P, Methyl 3-cyano
 4-(4-acetylthylamino)benzoate 1020043-10-8P, Methyl
 3-bromo-4-(4-acetylthylamino)benzoate 1020063-13-9P

L3 ANMER 42 OF 143 CAPUS COPYRIGHT 2009 ACS ON STN (Continued)



L3 ANMER 41 OF 143 CAPUS COPYRIGHT 2009 ACS ON STN (Continued)
 1020063-12-8P
 RI RCT (Reactant) / SPV (Synthetic preparation) / PREP (Preparation); RACT
 (Reactant or reagent)
 [prepn. of triazolinopyridazine deriva. as xanthine oxidase inhibitors
 for treatment of gout, inflammation, and ischemia-reperfusion injury]
 NI 1020063-09-5 CAPUS
 CN Benzoic acid, 4-(acetylthylamino)-3-cyano-, methyl ester (CA INDEX
 NAME)



NI 1020063-10-8 CAPUS
 CN Benzoic acid, 4-(acetylthylamino)-3-bromo-, methyl ester (CA INDEX
 NAME)



NI 1020063-11-9 CAPUS
 CN Benzoic acid, 4-(acetylthylamino)-3-cyano-, hydrazide (CA INDEX NAME)



NI 1020063-12-0 CAPUS
 CN Benzoic acid, 4-(acetylthylamino)-3-cyano-,
 2-(1-imino-4-pyridinylmethyl)hydrazide (CA INDEX NAME)

L3 ANMER 42 OF 143 CAPUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 2009148405 CAPUS
 DOCUMENT NUMBER: 148403229
 TITLE: Preparation of thiazololone derivatives as
 TNF-α converting enzyme (TACE) inhibitors
 INVENTOR(S): Kikuchi, Shinichi; Matsui, Takuya; Inoue, Teruhiko;
 Terashima, Masakazu; Naito, Tomoya; Minura, Takayuki;
 Fukui, Kenji; Takahashi, Atsuko
 PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
 SOURCE: RCT Int. Appl., 6/2009.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200809403	A1	20080403	MO 2007-095519	20070929
WI	AG, AL, AM, AT, AU, BG, BR, CA, CH, CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, LT, LU, LV, MD, ME, MK, MN, MU, MY, NG, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, TH, TR, TT, US, UA, UZ, VN	AT, BE, BG, BR, CA, CH, CN, CO, CZ, DE, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, LT, LU, LV, MD, ME, MK, MN, MU, MY, NG, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, TH, TR, TT, US, UA, UZ, VN	JP 2006-270244	A 20060930

PRIORITY APPL. INFO.: JP 2006-270244 A 20060930
 US 2006-850626P P 20061010

OTHER SOURCE(S): MARPAT 148403229
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AS The title compts. [1] Raa1, Raa2 = H, Cl-4 alkyl; na = 0-2; Laa1 =
 C(Raa1)(Raa2)O, O, G1, G2, etc.; Raa3, Raa4 = H, Cl-4 alkyl; Raa5-4 = H,
 halo, NO2, each (un)substituted CH, BR, NEH, OCH, Cl-4 alkyl, C3-12
 carbocyclyl, or heterocyclyl, etc.; nb = 0-1; rang J1, J2 = each
 (un)substituted saturated monocyclic heterocyclic or nonarom C3-8
 carbocyclo
 ring na = 0-1; ring le = each (un)substituted C3-12 carbocyclo ring or
 saturated monocyclic heterocyclo ring; la = C(Raa1)(Raa2)
 laa1-(Raa2)-CO-laa2, S(O)(Raa2), N(Raa2)(Raa2), O(Raa2), N(Raa2),
 N(Raa2)(Raa2)-Raa3-S, H, (un)substituted Cl-4 alkyl, Cl-7 alkoxy, C3-12
 aryl-Cl-7 alkoxy, C7-12 aroyl, etc.; laa1-4 = a bond, (un)substituted
 Cl-3 alkyl; la = C(Raa1)(Raa2)-CO-laa2, S(O)(Raa2), N(Raa2)(Raa2),
 (un)substituted NH, CO, CH(OM), Z, S(O), S(O)2, md, md2 = 0-2; Ld1, Ld2 =
 H, Cl-4 alkyl; le = each (un)substituted C3-12 carbocyclo, unsatd. fused
 heterocyclo, C2-4 alkyl; RE = H, Cl-4 alkyl or pharmaceutically
 acceptable salts thereof or hydrates thereof are prepared These compts.
 are

13 ABSTRACT 42 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)
 excellent an inhibiting activity against TNF- α converting enzyme (TACE), also called as a diisopeptidase and metalloprotease 17 (ADAM17) which cleaves pro-TNF- α to release TNF- α , and are selective inhibitors of TACE (ADAM17) over ADAM10 and ADAM14. Therefore, they are inhibitors of the action of TNF- α and can be used as pharmaceutical agents effective for the prevention or treatment of diseases associated with TNF- α such as inflammatory diseases, autoimmune diseases, allergic diseases, atopic diseases, transplant rejection, graft-vs.-host disease, cardiovascular diseases, sepsis/shock, infection, osteoporosis, diabetes, hyperlipidemia, Alzheimer's disease, neuropathy, organ fibrosis, rheumatoid arthritis, malignant tumor, and inflammatory bowel diseases (IBD). Thus, 0.002 g 5-(2-aminoethyl)-3H-[1,4,4a]thiadiazol-2-one hydrochloride, 0.040 g 4-(2-methylpiperidin-4-yl)methylbenzoate, and 1.0 mL DMF were mixed, sequentially treated with 0.030 mL N-methylmorpholine, 0.042 g 3-hydroxy-2-naphthoic acid monohydrate, and 0.030 g 1-hydroxy-1-(2-dimethylaminoethyl)carbodiimide hydrochloride, and stirred at room temp. for 7 h to give 69.

4-(2-methylpiperidin-4-yl)methyl-N-[2-(5-oxo-4,5-dihydro-1,4,4a-thiadiazol-2-yl)benzamide (III), 13 and 4-(2-methylpiperidin-4-yl)methyl-N-[13a,13b-2-(5-oxo-4,5-dihydro-1,4,4a-thiadiazol-2-yl)oxybenzyl]benzamide (III) in vitro showed IC50 of 50.60 \pm 0.0 and 65.05 \pm 0.05 μ M, resp., against recombinant human TACE (ADAM17). III in vitro inhibited the LPS-stimulated prodn. of TNF- α as TNF- α mRNA with IC50 of 41 μ M.

17 1016148-48-SP, (15,45)-3-[14-N-Acetyl-N-[2-methylpiperidin-4-yl]piperidin-1-carboxylic acid ethyl ester
 HPL (Pharmacological activity); SPR (Synthetic preparation); TSD (Toxicology test); KCS (Biological study); PKSP (Preparation); USES (Uses)
 [Preparation of thiazolidone derivs. as TNF- α converting enzyme (TACE) inhibitors]
 20 1016148-48-3 CAPLUS
 21 3-pyrrolidinemethanecarboxylic acid, 3-[[4-(acetyl[2-methyl-4-piperidinyl]methoxy]benzoyl]amino]-2-oxo-1,4-dioxane-1,7,4-thiadiazol-2-yl]-, ethyl ester, (35,45)- (CA INDEX NAME)

Absolute stereochemistry.



13 ABSTRACT 43 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM
 ACCESSION NUMBER: 1007745194 CAPLUS
 DOCUMENT NUMBER: 148126207
 TITLE: Preparation of
 2-(3-morpholin-4-yl)-6,7-dihydroxypropyl-2,3-dipyrrolidine
 5,6,7,8-tetrahydropropyl-2,3-dipyrrolidine derivatives
 as phosphatidylinositol 3-kinase (PI3K) inhibitors
 SHIMADA, Nobuo; KIKUCHI, Kikoyuki; OHMURA, Jun; KAWADA, Retsuro; NISHIMURA, Kenji; KAKIMOTO, Mitsuyuki; Yoshida, Myouki; Ishii, Nobuyuki; Kasegawa, Naomichi; Yamamoto, Shun; Koyama, Kohei
 CHUGAI SEIYAKU KENSHUKAI Kaisha, Japan
 PCT Int. Appl., 802pp.
 SOURCE: JP2007-282535
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	END. DATE	APPLICATION NO.	DATE
WO 20080218426	AL 200802214	WO 2007-745194	20070807
US, AU, BR, CA, CH, CN, DE, DK, ES, FR, GB, GR, HU, IL, IN, JP, KR, MA, MX, MY, NZ, PE, RU, SA, SG, SI, SK, TH, TR, TW, UA, US, VN, ZA, ZM, ZW	AL 200802214	WO 2007-745194	20070807
CA, CN, CH, CO, CR, CZ, DE, DK, ES, FR, GB, GR, HU, IL, IN, JP, KR, MA, MX, MY, NZ, PE, RU, SA, SG, SI, SK, TH, TR, TW, UA, US, VN, ZA, ZM, ZW	AL 200802214	WO 2007-745194	20070807
CA, CN, CH, CO, CR, CZ, DE, DK, ES, FR, GB, GR, HU, IL, IN, JP, KR, MA, MX, MY, NZ, PE, RU, SA, SG, SI, SK, TH, TR, TW, UA, US, VN, ZA, ZM, ZW	AL 200802214	WO 2007-745194	20070807
CA, CN, CH, CO, CR, CZ, DE, DK, ES, FR, GB, GR, HU, IL, IN, JP, KR, MA, MX, MY, NZ, PE, RU, SA, SG, SI, SK, TH, TR, TW, UA, US, VN, ZA, ZM, ZW	AL 200802214	WO 2007-745194	20070807
CA, CN, CH, CO, CR, CZ, DE, DK, ES, FR, GB, GR, HU, IL, IN, JP, KR, MA, MX, MY, NZ, PE, RU, SA, SG, SI, SK, TH, TR, TW, UA, US, VN, ZA, ZM, ZW	AL 200802214	WO 2007-745194	20070807
CA, CN, CH, CO, CR, CZ, DE, DK, ES, FR, GB, GR, HU, IL, IN, JP, KR, MA, MX, MY, NZ, PE, RU, SA, SG, SI, SK, TH, TR, TW, UA, US, VN, ZA, ZM, ZW	AL 200802214	WO 2007-745194	20070807
CA, CN, CH, CO, CR, CZ, DE, DK, ES, FR, GB, GR, HU, IL, IN, JP, KR, MA, MX, MY, NZ, PE, RU, SA, SG, SI, SK, TH, TR, TW, UA, US, VN, ZA, ZM, ZW	AL 200802214	WO 2007-745194	20070807
CA, CN, CH, CO, CR, CZ, DE, DK, ES, FR, GB, GR, HU, IL, IN, JP, KR, MA, MX, MY, NZ, PE, RU, SA, SG, SI, SK, TH, TR, TW, UA, US, VN, ZA, ZM, ZW	AL 200802214	WO 2007-745194	20070807
CA, CN, CH, CO, CR, CZ, DE, DK, ES, FR, GB, GR, HU, IL, IN, JP, KR, MA, MX, MY, NZ, PE, RU, SA, SG, SI, SK, TH, TR, TW, UA, US, VN, ZA, ZM, ZW	AL 200802214	WO 2007-745194	20070807

OTHER SOURCE(S): MARPAT 148126207

OR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AS The title compounds [1, X = a simple bond, CO, SO2, (CH3), (CH2), Y = a simple bond, a divalent linkage group selected from (un)substituted benzene and heterocycles such as pyrazole, pyrimidine, pyrazoline, oxadiazole, oxazole, thiazole, furan, thiophene, quinoline, etc.; provided X and Y are not simultaneously a simple bond; X = N, (un)substituted C-6 alkyl, ethynyl, halo, cyano, each (un)substituted CH2, SO2NH2, or NH2, etc.; K1 = each (un)substituted 7H-pyrrolyl, 3-pyrrolyl, 4-pyrrolyl, 5-pyrrolyl, or 2-, 3-, or 5-pyrrolyl, etc.] or (pharmaceutically acceptable salts thereof are prepared. These compounds have excellent in

13 ABSTRACT 42 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE IZ
 FORMAT

13 ABSTRACT 43 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE IZ
 FORMAT
 cancer. Thus, a soln. of 350 mg/mL 4-methoxybenzyl-[5-(2-morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrimidin-2-ylamine in 1:1:2 vol. of CHCl3 and satd. aq. NaHCO3 soln. (14 mL) was treated dropwise with 0.41 mL 20% phosphate/soln. soln., and stirred at room temp. for 1 h. The org. layer was sep'd, dried over MgSO4, and filtered, followed by distg. away the solvent under reduced pressure. The residue was dissolved in CHCl3, treated with 59 mg 2-methyl-5-morpholin-4-ylphenylamine and 50 μ L Et3N, stirred at room temp. overnight to give, after workup and silica gel chromatog., 4-(5-[4-(4-methoxybenzyl)amino]pyrimidin-5-yl)-2-(morpholin-4-yl)-5,6-dihydroxypropyl-2,3-dipyrrolidine-7-carboxylic acid N-[2-methyl-5-morpholin-4-yl]phenylamide (III) which was dissolved in CH2Cl2 and refluxed for a few hours to give 918 4-(2-morpholin-4-yl)-2-(morpholin-4-yl)-5,6-dihydroxypropyl-2,3-dipyrrolidine-7-carboxylic acid N-[2-methyl-5-morpholin-4-yl]phenylamide (III). II in vitro showed IC50 of 0.005 μ M against PI3 and inhibited colorectal cancer (HCT116), prostate cancer (PC3), and non-small cell


17 1007707-34-2P, N-[4-[[4-(3-hydroxypropyl)-2-(3-morpholin-4-yl)-5,6-dihydroxypropyl]-2-(3-dipyrrolidin-7-yl)carboxyl]phenyl]acetamide
 HPL (Pharmacological activity); SPR (Synthetic preparation); TSD (Toxicology test); KCS (Biological study); PKSP (Preparation); USES (Uses)
 [Preparation of 2-(3-morpholin-4-yl)-6,7-dihydroxypropyl-2,3-dipyrrolidine 5,6,7,8-tetrahydropropyl-2,3-dipyrrolidine derivs. as phosphatidylinositol 3-kinase (PI3K) inhibitors and antitumor agents]
 20 1007707-34-2 CAPLUS
 21 Acetamide, N-[4-[[5-(6-dihydro-8-(1-hydroxyphenyl)-2-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)carboxyl]phenyl]- (CA INDEX NAME)




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE IZ
 FORMAT

L3 ANSWER 49 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 Q alkyloxyethyl, alkoxyethoxymethyl, alkylammonioethyl, dialkylammonioethyl;
 = (unsaturated 5- or 6-membered azide, or unsat. heterocyclyl); A1 = N or CH₂; A2 = N or CH₃; A3 = N or CH₃; A4 = N or CH₃; A5 = H, halo, haloalkyl, cyanoalkyl, etc.; n = 1-4) are prep. as isocyanides, azides and azetides.

IT 951679-15-19 951679-20-19
 R1a RCT (Reaction); SPR (Synthetic preparation); PREP (Preparation); RACT (Reaction or reaction)
 (intermediate in preparation of oxazolidine derivative pesticide)
 R2 951679-15-1 CAPLUS
 C3 Benzamide, 6-(oxazolidino)-2-methyl-8-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



R2 951679-20-6 CAPLUS
 C3 Benzamide, 6-(oxazolidino)-2-methyl-8-(2-pyridylmethyl)- (CA INDEX NAME)



L3 ANSWER 50 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 20071177654 CAPLUS
 147148467

TITLE: Anaheterocycles, combinatorial library, focused library, pharmaceutical composition and methods for their preparation from isocyanides, primary amines, and amino-carboxylates or amino acid derivatives
 Inventor(s): Ivanishchev, Alexander Mikhailovich; Ilyin, Aleksei Petrovich; Knyal, Volodymyr Mikhailovich

Trifilevskov, Andrei Sergeevich; Tsirulnikov, Sergey Alexandrovich; Shkranov, Alexander Mikhailovich; Churakov, Marina Vladimirovna; Lomashina, Irina Gilegovna; Potegova, Viktor Vladimirovich; Sametdinova, Anastasiya Yilgizovna; Tashchikov, Sergey Yevgenyevich; Kravchenko, Dmitri Vladimirovich; Khvat, Alexander Viktorovich; Okun, Ilya Matveyevich; Rykachenko, Alexander Sergeevich

PATENT ASSIGNEE(S): FCI Int. Appl., 712pp.
 SOURCE: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400


DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

PATENT INFORMATION: "Chemical Diversity Research Institute" Ltd., Russia

INVENTOR INFORMATION: ORDER: P1400

DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACT. NUM. COUNTRY: 1

L3 ANSWER 50 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



A3 Anaheterocycles (I) W = anaheterocycle comprising 6-12 atoms, is optionally annulated, has at least one C1-7 carbonyl and/or heterocycle, and also comprises at least one O, S or N heteroatom; R1a = substituent as an amino group, excluding C1-6 alkyl, aryl or heterocycle containing at least one O, S or N heteroatom; R2 = carbonyl group

on C10(R2)a an R1a = substituent on the anaheterocycle, excluding H; R2 = substituent on the ring system, preferably C1-6 alkyl, aryl, or heterocycle containing at least one O, S or N heteroatom, or R2 and R1 together form

an amino-carboxy-methylene (C(R2)(CH2) group), of interest as potential physiologic active substances (anesthetics, antipsychotics, receptor modulators, enzyme inhibitors, antitubercular and antiparasitic agent etc.).

no data), are claimed, as are methods for their preparation, combinatorial and focused libraries comprising them and pharmaceutical compms. containing these

anaheterocycles as antitumor active ingredients. I are prepared by heterocyclization reactions of isocyanides with primary amines and either a mixture of (un)protected amino acids and amino-carboxylate esters or a bifunctional reagent in an organic solvent in presence of an acid catalyst.

One of these anaheterocycles (II; preparation) showed 59% and growth inhibition for cancer cell lines BLD-1, D7-143 and T-47b, resp., and pharmaceutical compms. for II in tablets, capsules and injections are given.

IT 951640-33-49
 R1a CYN (Combinatorial preparation); RAC (Pharmaceutical activity); TRU (Therapeutic use); BIO (Biological study); COM (Combinatorial study); PREP (Preparation); USE (Use)

(claimed compound; preparation of combinatorial and focused libraries and pharmaceutical compms. of anaheterocycles and their anticancer activities)

R2 951640-33-8 CAPLUS
 C3 Anaheterocycle, 8-[4-methyl-2-[(9-[(3-methylbutyl)amino]piperidin-4,2,2,1-tetrahydroquinolin-3-yl)amino]piperidin-1-yl]- (CA INDEX NAME)


L3 ANSWER 50 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



REFERENCE COUNTRY: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT

L3 ANSWER 53 OF 143 CAPUS COPYRIGHT 2009 ACS ON STN (Continued)




PAGE 1-B

L3 ANSWER 53 OF 143 CAPUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 20071121499 CAPUS
 DOCUMENT NUMBER: 147427649
 TITLE: Preparation of 3,6-bisubstituted 9,12-oxolide erythromycin analogs as antibacterial agents
 INVENTOR(S): Dr. Tat Tany Niu, Benjamin Wang, She
 PATENT ASSIGNER(S): Nanta Pharmaceuticals, Inc. USA
 SOURCE: U.S. Pat. Appl. Publ., N/A
 COUNTRY: US/CA
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 KIND DATE APPLICATION NO. DATE
 IN 2007032204 A 20071004 US 2006-437493 20060314
 US 7407942 E2 20060505 US 2006-70667P P 20040719
 PRIORITY APPL. INFO.:
 OTHER SOURCE(S): CASREACT 147427649; MARPAT 147427649
 CI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The present invention discloses the preparation of 3,6-bisubstituted 9,12-oxolide erythromycin analogs I, wherein R1 is H, D, Me, alkyl, CH2OH, aryl, alkenyl, alkynyl; R2 is H, CH, CH2 when R1 is H, CH, CH2, HNE, CH, heterocycle, alkyl; A is O, COOEt, S, SO, SO2, NH, SH, NHCO, CHCO, NHCO, NHCO; R3 is H, aryl, heterocycle, alkyl, alkenyl, alkynyl; S and T are independently H, CH, CH2, HNE, CH, heterocycle, alkyl; X together with the oxygen which they are attached form O, substituted oxime; B is substituted N, V is H, acid, cyano, nitro, aldehyde, carboxylic acid, amide, aliphatic; Q is H, protected CH, CH, O-aryl, O-alkyl, O-alkenyl, O-alkynyl; C-cycloalkyl; L is Et, CH2OH, Me, alkyl, alkenyl, alkynyl; R is H, hydroxy protecting group, or pharmaceutically acceptable salts, esters, or prodrugs which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention. Thus, erythromycin analog II was prepared and tested in vitro as antibacterial agent. The compounds of

L3 ANSWER 53 OF 143 CAPUS COPYRIGHT 2009 ACS ON STN (Continued)
 The invention generally demonstrated an MIC in the range from about 64 µg/mL to about 0.01 µg/mL. According to the methods of treatment of the present invention, bacterial infections, cystic fibrosis and inflammatory conditions are treated or prevented in a patient such as a human or another animal by administering to the patient a therapeutically effective amt. of a compd. of the invention, in such amt. and for such time as is necessary to achieve the desired result.
 IT 511514-19-6P
 N/A PAC (Pharmacological activity); SH (Synthetic preparation); TH (Therapeutic use); R2C (Biological study); P2C (Preparation); USES (Uses)
 (Preparation of 3,6-bisubstituted 9,12-oxolide erythromycin analogs as antibacterial agents)
 RU 511514-13-0 CAPUS
 CH Erythromycin, 3,6-O-[2-[[4-(acetylaminophenyl)methyl]imino]-1,3-propenediyl]-3-O-de-12,6-ideoxy-3-O-methyl-3-O-methyl-4-O-1-(hydroxyoxanonyl)-9-deoxy-11,12-dideoxy-9,15-epoxy-11-oxo-, (10E,12E)-(CA INDEX 3008)
 Absolute stereochemistry.
 Double bond geometry unknown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE EE FORMAT


L3 ANSWER 54 OF 143 CAPUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 20071110441 CAPUS
 DOCUMENT NUMBER: 147427738
 TITLE: Preparation of imidazolidinone derivatives as 11P-BD1 inhibitors
 INVENTOR(S): Takahashi, Hiroshi; Takahashi, Hiroshi; Nakano, Akiko; Tanaka, Hiroaki
 SOURCE: Taisho Pharmaceutical Co., Ltd., Japan
 PATENT ASSIGNER(S): Jpn. Kokai Tokkyo Koho, 88p.
 COUNTRY: JP/CA/JP
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 KIND DATE APPLICATION NO. DATE
 JP 2007254409 A 20071004 JP 2006-82507 20060324
 PRIORITY APPL. INFO.: JP 2006-82507 20060324
 OTHER SOURCE(S): MARPAT 147427738
 CI




AB Title compd. I [A = aromatic hydrocarbon ring, condensed aromatic hydrocarbon ring-saturated ring, heterocyclic ring, etc.]; R1, R2 = H, halo or alkyl; R3 = H, halo, hydroxy, etc.; R4 = halo, alkyl or alkyl substituted with halo or hydroxy; R5, R6 = H, alkyl, benzyl, etc.; R7 = alkyl, alkenyl, cycloalkyl.

- L3 ANSWER 55 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 etc.] or pharmaceutically acceptable salts, hydrates or solvates thereof were prep. For example, reaction of N-[15-(1-phenylethyl)ethane-1,2-diamine], e.g., prep. from 15-(1-phenylethyl)amine in 3 steps, with triphosgene followed by treatment with benzyl bromide afforded compd. 11 [R = phenyl]. In 11p-BED1 inhibition assays, the IC50 value of compd. 11 [R = naphthalen-2-yl] was 2-3 nM. Compds. 1 are claimed useful for the treatment of diabetes, metabolic syndrome, obesity, etc.
- IT 912442-35-67
 E1 PAC (Pharmacological activity); SPN (Synthetic preparation); TSD (Therapeutic use); RCL (Biological study); PREP (Preparation); USKS (Uses)
- EN 951445-31-8 CAPLUS
 CN [Preparation of indololidone derivs. as 11p-BED1 inhibitors]
- EN 951445-31-8 CAPLUS
 CN Acetanilide, N-[4-[(15S)-1-(2-oxo-3-[(15S)-1-phenylethyl]-1-indololidonyl)ethyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



- L3 ANSWER 55 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 2007094327 CAPLUS
 DOCUMENT NUMBER: 1481517859
 TITLE: Synthesis of acetylene derivatives of lappaconitine
 AUTHOR(S): Vasilevskii, S. F.; Oskochii, S. A.; Shul'ts, E. E.; Polubinskiy, E. V.; Stepanov, A. A.; Tolstikov, G. A.
 CORPORATE SOURCE: Institute of Chemical Kinetics and Combustion, Siberian Division, Russian Academy of Sciences, Novosibirsk, 630090, Russia
 SOURCE: Doklady Chemistry (2007), 431(2), 191-195
 CODEN: DOKCHY; ISSN: 0013-0809
 PUBLISHER: Pleiades Publishing, Ltd.
 JOURNAL: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 1481517859
 CI




1

- AB A methods for the preparation of halogenated derivs. 1 (R2' = CO2Me, R3' = H, R4' = H, R5' = CO2Me, R3' = H, R5' = Iodo; R2' = H, R3' = H, R4' = H, R5' = H, R5' = Iodo) of the acetonitine alkaloid lappaconitine 1 (R2' = CO2Me, R3' = H, R5' = I) and N-acetyl lappaconitine 1 (R2' = H, R3' = H, R5' = I) was presented. Acetylene derivs. 1 (R2' = CO2Me, R3' = H, R5' = C-triphenyl, R4' = CH2OH, C(OH)Me), Ph, pyridin-5-yl) were subsequently prepared via cross-coupling reactions of 5'-iodolappaconitine 2 (R2' = CO2Me, R3' = H, R5' = Iodo) with the corresponding alkynes, Hg(Tp)2/NaOMe, R-g, 1 (R2' = CO2Me, R3' = H, R5' = C-triphenyl, C(OH)Me) was prepared with 72% yield by reacting 5'-iodolappaconitine with propargyl alc. using CuI, PdCl2(PPh3)2, PPh3 and Et3N in benzene at 60-65° under an argon atmosphere
- IT 1020209-81-7P 1020209-82-8P 1020209-83-9P
 1020209-84-0P
 EN: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of acetylene derivs. of lappaconitine via cross-coupling)


- L3 ANSWER 55 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 reactions of alkynes with 5'-iodolappaconitine:
- EN 1020209-81-7 CAPLUS
 CN Acetanilide-4,8,9-triol, 20-ethyl-1,14,16-trimethoxy-, 4-[(2-(acetylaminoo)-5-(2-hydroxy-1-propen-1-yl)benzoate), (14a,14a,14b)- (CA INDEX NAME)

Absolute stereochemistry.



- EN 1020209-82-8 CAPLUS
 CN Acetanilide-4,8,9-triol, 20-ethyl-1,14,16-trimethoxy-, 4-[(2-(acetylaminoo)-5-(2-hydroxy-1-methyl-1-buten-1-yl)benzoate), (14a,14a,14b)- (CA INDEX NAME)


Absolute stereochemistry.



- EN 1020209-83-9 CAPLUS
 CN Acetanilide-4,8,9-triol, 20-ethyl-1,14,16-trimethoxy-, 4-[(2-(acetylaminoo)-5-(2-phenylethyl)benzoate), (14a,14a,14b)- (CA INDEX NAME)


Absolute stereochemistry.

- L3 ANSWER 55 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




- EN 1020209-84-0 CAPLUS
 CN Acetanilide-4,8,9-triol, 20-ethyl-1,14,16-trimethoxy-, 4-[(2-(acetylaminoo)-5-[2-(5-pyridinyl)ethyl]benzoate), (14a,14a,14b)- (CA INDEX NAME)

Absolute stereochemistry.



- REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

13 ANHER 56 OF 143 CAPUS COPYRIGHT 2009 ACS ON STM
ACCESSION NUMBER: 2007:934293 CAPUS
DOCUMENT NUMBER: 16745067
TITLE: Synthesis and structure-activity relationships of new 4-(6-iodo-8-indazolo[1,2-a]pyridin-2-yl)-8-dimethylbenzenamine derivatives as ligands for human β -amyloid plaques
AUTHOR(S): Chakraborty, Chandra; Jang, Joon; Sebastian, Bernar, Mary M.; Doganlar, Cansu; Middaowen, David A.; Simla, Joseph B.; Pyle, Victor M.
CORPORATE SOURCE: Molecular Imaging Branch and Clinical Brain Disorders Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, 20895, USA
SOURCE: Journal of Medicinal Chemistry (2007), 50(19), 4366-4378
CODEN: JMCMAJ; ISSN: 0022-2625
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 347-04067
GI



AB A set of 4-(6-iodo-8-indazolo[1,2-a]pyridin-2-yl)-8-dimethylbenzenamine (DMT) deriva., e.g., 1 [R = Br (11), Me (11)], were synthesized and assayed for affinity toward human β plaques. Analogs with 6-ethylthio, 6-cyano, 6-amino, and 6-p-methoxyphenylthio were discovered to have high affinity ($K_i < 30$ nM). However, introduction of


a hydrophilic thioether group in the 6-position reduced or abolished affinity. In secondary 9-Me analogs, bromo substituents both in 3- and 6-positions (12) imparted high affinity ($K_i = 7.4$ nM), whereas a Me substituent at 3-position (13) did not. The tolerance for nonhydrophilic thioether substituents in the 6-position opens the possibility of developing new sensitive positron emission tomog. radioligands for imaging human β plaques in Alzheimer's disease, especially in view of the suitability of thioethers to be labeled with iodine-123 or fluorine-18 through S-alkylation reactions. The structure-activity relationships revealed in this study extends insight into the topology of the binding site for DMT-like ligands in human β plaques.

IT 93135-33-39
RI RCT (Reactant); SYN (Synthesis preparation); PREP (Preparation); RACT (Reactant or reagent)
[preparation, human β -amyloid plaque affinity and SAR of

13 ANHER 57 OF 143 CAPUS COPYRIGHT 2009 ACS ON STM
ACCESSION NUMBER: 2007:943297 CAPUS
DOCUMENT NUMBER: 16735062
TITLE: Preparation of 3-chloro-4-isopropoxybenzamide and 3-cyano-4-isopropoxybenzamide derivatives as inhibitors of autotrophic kinases
INVENTOR(S): Qian, Xiaopang; McDonald, Andrew J.; Zhou, Han-Jie; Ashcraft, John W.; Yao, Hany; Zhang, Rong; Huang, Jennifer; You Chen; Wang, Jianchao; Morgan, David J.; Morgan, Bradley P.; Bergman, Gertur; Shank, Rajagopal; Knight, Steven D.; Adams, Nicholas D.; Parrish, Cynthia A.; Duffy, Kevin; Flitch, Duke; Tedesco, Rosanna
PATENT ASSIGNER(S): USA
SCORE: U.S. Pat. Appl. Publ., 23pp., Cont.-in-part of U.S. Ser. No. 323,709.
CODEN: USPOCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION: 4

PATENT NO.	INTD	DATA	APPLICATION NO.	DATA
US 2007037483	A1	20070823	US 2005-124058	20050506
US 2006049708	A1	20060504	US 2005-123709	20050503
US 2006024789	A1	20060302	US 2005-273147	20050109
US 7044413	A	20090317		
US 2008023332	A1	20080206	US 2008-7143	20080307
PRIORITY APPL. INFO.			US 2004-569309	P 20040506
			US 2005-126109	A2 20050503
			US 2005-124058	A3 20050506
			US 2005-273147	A3 20050109

OTHER SOURCE(S): NAPSAT 147:30062
GI



AB Title compds. 1 [R2 = (unsubstituted (hetero)aryl, heterocyclyl); R = CO2R, SO2R; R3 = H, (unsubstituted lower alkyl); W = CH4, CH2CH4, H; R3 = CO2R, R, CH, (unsubstituted alkyl, heterocyclyl, aryl, heterocyclyl); R4 = H, (unsubstituted alkyl); R5 = H, H, (unsubstituted alkyl, heterocyclyl, lower alkyl); R6 = H, (unsubstituted alkyl, alkoxyl, heterocyclyl,

13 ANHER 58 OF 143 CAPUS COPYRIGHT 2009 ACS ON STM (Continued)
N-dimethyl[1-(odo)aminooxydicyl]benzenamine deriva. starting from amino(halo)pyridines, aminopyrazines, and (heteroaryl)benzenamines
RI 95123-53-3 CAPUS
CN Acetamide, N-[4-(2-bromophenyl)-2-methylphenyl]-8-methyl-1-CA INDEX NAME




AMERICAN CHEMICAL SOCIETY
THIS
FORMAT
58 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

13 ANHER 59 OF 143 CAPUS COPYRIGHT 2009 ACS ON STM (Continued)
alkoxy(hetero)aryl, aminocyclopropyl, (hetero)aryl, etc.; R1 = H, (unsubstituted lower alkyl, aryl, amino, alkoxyl, or alkoxy provided that if W is H, then R1 is not hydroxy or (unsubstituted amino, and R6 not optionally substituted alkoxyl, optionally substituted alkoxyl, optionally substituted heteroalkoxy, or optionally substituted amino, and their pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and their salts.) are prepd. Comps.

1 including N-benzyloxy-amino alcoh., N-benzyloxy-amino acid amide, N-benzyloxyaminoalcohol, and N-benzyloxy-diamine deriva. are inhibitors of one or more mitotic kinases and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders, fungal disorders, and inflammation by modulating the activity of one or more mitotic kinases. Thus, cyclocondensation of (2S)-2-(tert-butoxycarbonylamino)-5-hydroxy-6-oxopentanoic acid Me ester with thiosemamide in the presence of diisopropylethylamine in methanol under refluxing for 24 h gave (2S)-2-(tert-butoxycarbonylamino)-3-(2-phenylthio)-4-ylpropanoic acid which was treated with CF3COOH in CH2Cl2 at room temp. for 10 min to give (2S)-2-amino-3-(2-phenylthio)-4-ylpropanoic acid (17). It was condensed with 3-chloro-4-isopropoxybenzamide acetonitrile/ester in the presence of diisopropylethylamine in DMF at room temp. to give (2S)-N-methyl-3-[3-(3-chloro-4-isopropoxybenzoylamino)-3-(2-phenylthio)-4-yl]propanoic acid (18). Selected 3 showed G550 1504 growth inhibition (com.) of 510 nM against human ovarian tumor cells Shov-3.

IT 943297-04-09, [(1S)-2-(tert-butoxycarbonylamino)-3-(4-[R-(3,3-dimethyl-2-oxobutyl)formylamino]phenyl)propyl]ethyl-(tert-butoxy)dimethylamine
RI RCT (Reactant); SYN (Synthesis preparation); PREP (Preparation); RACT (Reactant or reagent)
[preparation of N-benzyloxy amino alcoh., N-benzyloxy-amino acid, and N-benzyloxyaminoalcohol derivatives as inhibitors of mitotic kinases]
RI 943297-04-09 CAPUS
CN Carbanic acid, N-[12]-2-[[[1,4-dimethylthiophenylthiyl]oxy]-2-[[4-[[1,4-dimethyl-2-oxobutyl]formylamino]phenyl]thiyl]ethyl]-, 1,1-dimethylthiyl ester (CA INDEX NAME)

Absolute stereochemistry.





L3 ANWEX 61 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)



AB Title compds. I, wherein A can be an aryl or heteroaryl ring system; R can be H, hydroxy, amino, alkyl, cycloalkyl, halo, cyano, etc.; R1 is H, hydroxy or lower alkyl; R2 is H or lower alkyl are prepared for the treatment of diseases related to trace amine associated receptors.


Thus, I was prepared and displayed a Ki of 0.507 μ M in a mouse on 7AHL. Further, I can be successfully employed as a prodrug in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, mood disorders such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

IT 341543-88-9
R1: HOC (Pharmacological activity); SPH (Synthetic preparation); TMO (Therapeutic use); R1OL (Biological study); PREP (Preparation); USBS (Uses)

[preparation of substituted 2-imidazole-imidazoline deriva. for the treatment of diseases related to trace amine associated receptors]

RI 341543-88-6 CAPLUS

CH Acetamide, N-[4-[[4,5-dihydro-1H-imidazol-2-yl)methyl]phenyl]-, hydrochloride (I-1) (CA INDEX NAME)



● R1

IT 341543-87-7

R1: HOC (Reagent); RACT (Reagent or reagent)

[preparation of substituted 2-imidazole-imidazoline deriva. for the

L3 ANWEX 62 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNTRY:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007095565	A1	20070908	WO 2007-EP05052	20070119
US	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BT, BE, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DR, ES, EU, FI, FR, GB, GR, GM, GU, HK, HN, HU, IL, IN, JP, KE, KG, KM, KN, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MV, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SV, SY, TD, TH, TJ, TT, TZ, UA, UG, US, UZ, VC, VE, VN, ZA, ZM, ZW			
EP 1983939	A1	20081029	EP 2007-732059	20070119
US	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BT, BE, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DR, ES, EU, FI, FR, GB, GR, GM, GU, HK, HN, HU, IL, IN, JP, KE, KG, KM, KN, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MV, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SV, SY, TD, TH, TJ, TT, TZ, UA, UG, US, UZ, VC, VE, VN, ZA, ZM, ZW			
PRIORITY APPL. INFO.			US 2006-762905P	F 20060126
			US 2006-847879P	P 20060129
			US 2006-847879P	P 20060129
			WO 2007-EP05052	M 20070119

OTHER SOURCE(S):

CI


CASREACT 147:228757; MANPAT 147:228757

L3 ANWEX 63 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)

treatment of diseases related to trace amine associated receptors)

RI 345541-87-7 CAPLUS

CH Acetamide, N-[4-[[4,5-dihydro-1H-imidazol-2-yl)methyl]phenyl]- (CA INDEX NAME)



AB Title compds. I, wherein A can be an aryl or heteroaryl ring system; R can be H, hydroxy, amino, alkyl, cycloalkyl, halo, cyano, etc.; R1 is H, hydroxy or lower alkyl; R2 is H or lower alkyl are prepared for the treatment of diseases related to trace amine associated receptors.

Thus, I was prepared and displayed a Ki of 0.507 μ M in a mouse on 7AHL. Further, I can be successfully employed as a prodrug in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, mood disorders such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

IT 341543-88-9
R1: HOC (Pharmacological activity); SPH (Synthetic preparation); TMO (Therapeutic use); R1OL (Biological study); PREP (Preparation); USBS (Uses)

[preparation of substituted 2-imidazole-imidazoline deriva. for the treatment of diseases related to trace amine associated receptors]

RI 341543-88-6 CAPLUS

CH Acetamide, N-[4-[[4,5-dihydro-1H-imidazol-2-yl)methyl]phenyl]-, hydrochloride (I-1) (CA INDEX NAME)



● R1

IT 341543-87-7

R1: HOC (Reagent); RACT (Reagent or reagent)

[preparation of substituted 2-imidazole-imidazoline deriva. for the

L3 ANWEX 64 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:


DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNTRY:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007095565	A1	20070908	WO 2007-EP05052	20070119
US	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BT, BE, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DR, ES, EU, FI, FR, GB, GR, GM, GU, HK, HN, HU, IL, IN, JP, KE, KG, KM, KN, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MV, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SV, SY, TD, TH, TJ, TT, TZ, UA, UG, US, UZ, VC, VE, VN, ZA, ZM, ZW			
EP 1983939	A1	20081029	EP 2007-732059	20070119
US	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BT, BE, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DR, ES, EU, FI, FR, GB, GR, GM, GU, HK, HN, HU, IL, IN, JP, KE, KG, KM, KN, KR, KZ, LA, LC, LG, LI, LU, LV, LY, MA, MD, MG, MK, MN, MU, MV, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SV, SY, TD, TH, TJ, TT, TZ, UA, UG, US, UZ, VC, VE, VN, ZA, ZM, ZW			
PRIORITY APPL. INFO.			US 2006-762905P	F 20060126
			US 2006-847879P	P 20060129
			US 2006-847879P	P 20060129
			WO 2007-EP05052	M 20070119



REFERENCE COPY:


4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

10/562,112


13 ANWER 64 OF 143 CAPUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

13 ANWER 65 OF 143 CAPUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:77559 CAPUS
147:36426
DOCUMENT NUMBER:
TITLE:
AUTHOR(S):
Shang, Qingyong; Li, Xiaojiao; Allan, George F.;
Shrivastava, Tishan; Liskow, Oliver; London, Scott C.;
Sui, Zhaohua
CORPORATE SOURCE:
Drug Discovery, Johnson & Johnson Pharmaceutical
RESEARCH AND DEVELOPMENT, LLC, KENIL, PA, 19141, USA
SOURCE: 3857-3859
COUNTRY: (FRANCE); ISSN: 0022-2623
JOURNAL OF MEDICINAL CHEMISTRY (2007), 50(16),
AMERICAN CHEMICAL SOCIETY
DOCUMENT TYPE:
JOURNAL
LANGUAGE:
OTHER SOURCE(S):
ENGLISH
CASREACT 147:36426
C1



AB A series of pyrazolines have been designed, synthesized, and evaluated by in vivo screening as tissue-selective androgen receptor modulators (SRMs). Structure-activity relationships (SAR) were investigated at the substitution positions as well as the core pyrazoline ring and the amide linker. Overall, strong electron-withdrawing groups at the substitution positions were optimal for SR agonist activity. The (R)-isomer of 1 exhibited more potent SR agonist activity than the corresponding (S)-isomer. (S)-2 exhibited an overall partial androgenic effect but anabolic effect via oral administration in castrated rats. It demonstrated a noticeable anabolic effect on prostate in intact rats with endogenous testosterone. Thus, (S)-1 is a tissue-selective nonsteroidal androgen receptor modulator with agonist activity on muscle and mixed agonist and antagonist activity on prostate.

IT 94912-92-9
RI ACT (Reactant) RACT (Reactant or reagent)
Preparation of N-aryl pyrazolines from amides using N-aryl acrylamides as
key intermediates and heterocyclization as key step, and their Biol.
activity as tissue-selective androgen receptor modulators and SRMs.
NH 94912-92-9 CAPUS
CN Benzenesulfonic acid, 4-methyl-, (2E)-2-[2-(4-

13 ANWER 66 OF 143 CAPUS COPYRIGHT 2009 ACS on STN (Continued)

147:36426 CAPUS

DOCUMENT NUMBER: 147:36426

TITLE: Preparation of triazine-2,4-dione derivatives as

prokineticin 1 receptor antagonists

AUTHOR(S): Gatta, Steven J.; Dykstra, Alexey B.; He, Wei; Lasko,

Joseph; Miskowski, Tamara A.; Balbovsky, Janet L.;

Schulz, Mark

CORPORATE SOURCE: Janssen Pharmaceutica N.V., Belg.

SOURCE: RCT Int. Appl., 28pp.

COUNTRY: (FRANCE)

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2007079163 A2 20070712 WO 2004-084946 20041228

WO 2007079163 A3 20070930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BY, BE, CA, CH,

CN, CO, CU, CY, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB,

GR, GU, GM, GT, HN, HR, HU, ID, IL, IN, JP, KE, KG, KH, KR,

KP, KZ, LA, LG, LI, LU, LV, LY, MA, MC, MD, ME, MG, MK,

MN, MU, MV, MW, MY, MZ, NA, NE, NG, NI, NO, NZ, OM, PA,

PE, PG, PH, PK, PL, PT, RO, RU, SA, SD, SE, SG, SI, SK, SL,

TH, TN, TR, TT, UA, UG, US, VE, VC, VN, ZA, ZM, ZW

M: AT, BA, BG, BR, CA, CH, CN, CO, DE, EE, ES, FI, FR, GB,

HU, IL, IN, IT, JP, KE, KG, KR, KZ, LA, LV, LY, MA, MC,

MD, ME, MG, MK, MN, MU, MV, MW, MY, MZ, NA, NE, NG,

NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SA,

SD, SE, SG, SI, SK, SL, TH, TN, TR, TT, UA, UG, US, VE,

VC, VN, ZA, ZM, ZW

CA 2635842 A3 20070713 CA 2004-2635842

EP 1973886 A2 20081001 EP 2004-849064

FI 177886 A1 20080215 FI 2004-849064

US 20080215213 A1 20080215 US 2004-849064

US 20080215213 A1 20080215 US 2004-849064

JP 20080215213 A 20080215 JP 2004-849064


PRIORITY APPL. INFO.: US 2005-749399 P 20051229

WO 2004-084946 W 20041228


OTHER SOURCE(S): NABPAT 147:36426

C1

L3 ANSWER 70 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)



1



2

AS Title compds. 1 [R1 = mono or bicyclic heteroaryl, or pyridin-2-onyl (wherein said heteroaryl is optionally substituted with R2); R2 = -H, halo, alkyl, etc.; R3 = -H, mono or bicyclic heteroaryl, 3-(4-methoxybenzyl)-N-quinoxalin-4-on-6-yl, etc. (wherein said Ph, heteroaryl or benzo-fused heteroaryl) are optionally substituted with -OR, alkyl, Ph, etc.); R4, R5 = H, alkyl, etc.; R1, R2 = H, halo, alkyl and benzofused, proparg, phenanthro-10-yl; lipophilic salts, solvates, and stereoisomers thereof were prepared for example, NcPP1) catalyzed coupling reaction of 3,4-dichloropyridine with 1-methyl-4-(4,4,4-trifluoromethyl)-1,1,2,2-tetraazobenzene-3-yl)-N-tryptan followed by treatment with quinoxaline-4-pyruvic acid hydrazide afforded compound 2. To cell based MTTA assay for α -Met phosphorylation, compound 2

showed the IC50 value of 0.04 μ M. Compds. 1 are claimed useful for the treatment of cancers and other cell proliferative disorders.

21 341340-07-09
R1: PAC (Pharmacological activity); R2: (Reactant); R3: (Synthetic preparation); R4: (Therapeutic use); R5: (Biological study); R6: (Preparation); R7: (Reactant or reagent); R8: (Use) (Preparation of triazopyridazines as tyrosine kinase modulators)

22 341340-41-2 CAPLUS
23 Acetamide, N-[4-[(2-thienyl)-1,2,4-triazolo[4,3-b]pyridin-3-yl)methyl]phenyl]- (CA THREE NAME)

L3 ANSWER 71 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)


ACCESSION NUMBER: 2007/701211 CAPLUS
DOCUMENT NUMBER: 147143860
TITLE: Preparation of 3-chloro-4-isopropoxybenzamide and 3-cyano-4-isopropoxybenzamide derivatives as inhibitors of nuclear kinases

INVENTOR(S): Qian, Xiaoping; Ahnert, Luke W.; Wang, Jianchao; Yao, Xinyi; Zhang, Hong; Bergmeier, Gustavo; Morgan, Bradley P.; Morgan, David J.; Shahan, Dushyant; Wright, Steven P.; Adams, Nicholas D.; Parrish, Cynthia A.; Duffey, Kevin J.; Fitch, Duke Tadeo; Joannas, U.S. Pat. Appl. Publ., 37pp., Cont.-in-part of U.S. Ser. No. 271,347.

PATENT ASSIGNEE(S): COEUS
SOURCE: US
COUNTRY: US
DOCUMENT TYPE: English
LANGUAGE: English
FAMILY ACC. NUM. COUNTRY: 4
PATENT INFORMATION: 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070149316	A1	20070628	US 2005-059250	20051109
US 20060247289	A1	20061102	US 2005-271147	20051109
US 7034412	B2	200909317	US 2004-569310	P 20040506
PRIORITY APPL. INFO.			US 2005-121709	A2 20050503
			US 2005-124608	A2 20050506

OTHER SOURCE(S): MARRIOTT 147,143860
GI



3

AS The title compds. [1, R1 = 3-halo-4-(R2)-1,1,1-trifluoropropan-2-yl(methyl), 3-cyano-4-(R2)-1,1,1-trifluoropropan-2-yl(methyl), 3-halo-4-isopropoxybenzyl(methyl), 3-cyano-4-isopropoxybenzyl(methyl), 3-halo-4-(R2)-1,1,1-trifluoropropan-2-yl(methyl), 3-cyano-4-(R2)-1,1,1-trifluoropropan-2-yl(methyl); R2 = OCH3, R3 = H, (unsubstituted lower alkyl, W = CH3, CH2CH3, N3 = CO2R, R4 = each unsubstituted substituted alkyl, heterocycloalkyl, heteroaryl, or aryl, cyano, sulfonyl; R5 = H,

L3 ANSWER 70 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)



REFERENCE COMPT:

FORMAT

3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE FE

L3 ANSWER 71 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STM (Continued)

(unsubstituted alkyl; R5 = H, R6, each (unsubstituted alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, or lower alkyl; R6 = H, COR2, (unsubstituted alkyl, alkyl, aryl, heteroaryl, heterocycloalkyl, heteroalkoxy, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl; R7 = R8, each (unsubstituted lower alkyl, aryl, alkyl, aralkoxy, or alkyl), provided that if R4 is H, then R5 is not hydroxy or (unsubstituted amino, and R6 is not optionally substituted alkyl, optionally substituted alkyl, optionally substituted heteroalkoxy, or optionally substituted amino) are prep. (18)-3-(methoxybenzylamino)-1-[4-[4-[(18)-2-[[14-((18)-2,2,2-trifluoroisopropyl)oxy]-3-chlorophenyl]methoxy]amino]-4-hydroxybutyl]phenyl]-1-ethylamide-2-yl]ethanes. These compds. including


H-benzoyl-amino alcs., H-benzoyl-amino amino acids, H-benzoylaminocarbamides, and H-benzoyl-diamine derivs. are inhibitors of one or more mitotic kinases and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasia, reformation, cardiac hypertrophy, immune disorders, fungal disorders, and inflammation by modulating the activity of one or more mitotic kinases. Thus cyclization of (18)-3-(tert-butoxybenzylamino)-5-bromo-4-isopropoxyaniline Me ester with thiodianine in the presence of diisopropylethylamine in methanol under refluxing for 24 h gave (18)-3-(tert-butoxybenzylamino)-3-(2-phenylthio)-4-yl]propanoic acid which was treated with CF3CO2H in CH2Cl2 at room temp. for 10 min to give (18)-2-amino-3-(2-phenylthio)-4-yl]propanoic acid (11). 11 was condensed with 3-chloro-4-isopropoxybenzoic acid pentafosforyl ester in the presence of diisopropylethylamine in DMF at room temp. to give

(25)-N-methyl-2-[3-chloro-4-isopropoxybenzylamino]-3-(2-phenylthio)-4-yl]propanamide (11). Many of the compds. 1 showed 0.15 (50% growth inhibition concn.) of SIO μ M against human ovarian tumor cells Show-5.


27 942929-04-99, [(18)-2-(tert-butoxybenzylamino)-3-(4-[(18)-2,2-dimethyl-2-oxoethyl]formylamino)phenyl]propyl]tert-butylidimethylsilane
R1: RCT (Reactant) SYN (Synthetic preparation); R2: PREP (Preparation); R3: (Reactant or reagent) (Preparation of H-benzoyl amino alcs., H-benzoyl-amino acids, and H-benzoylaminocarbamides derivs. as inhibitors of mitotic kinases)

28 942929-04-99 CAPLUS
29 Catechol acid, H-[18]-2-[[1,1,1-dimethylethyl]dimethylthyl]oxy]-1-[4-[(18)-3-dimethyl-2-oxoethyl]formylamino]phenyl]methylthyl]-, 1,1-dimethylethyl ester (CA THREE NAME)

Absolute stereochemistry.



L3 ANSWER 75 OF 143 CAPLES COPYRIGHT 2022 ACS on STN (Continued)



22 Title compds. [I]; A = Ph, naphthyl, heterocaryl; B = atoms to form (substituted) diazanyl, pyrazyl, cyclohexyl, Ph, pyridyl, etc.; X, Y = (substituted) alkylenes; R1a, R1b, R1c = null, H, halo, OH, CO2R, cyano, NO2, (substituted) alkyl, alkoxy, alkoxy-carbonyl, Ph, PhO, PhO2C, etc.; R2 = H, (substituted) alkyl, cycloalkyl, Ph); were prepared. Thus, title compound [II] was prepared in 3 steps from

1,3-dibromopropane, 3,4-dihydroxybenzaldehyde, isobutylamine, and 4-benzylmorpholine-2-carboxylic acid hydrochloride. I generally showed proizetacin 2 receptor antagonism with IC_{50} <10 μ M.

```


17 94170-64-8P
    EL: PAC (Pharmacological activity); SYN (Synthetic preparation);
    (Therapeutic use); BCL (Biological study); PREP (Preparation); U
    (Uses)
    [claimed compound; preparation of morpholinecarboxanides as
    prokineticin 2

```


```

receptor antagonists)
R2  941707-6-8 CAPLOS
CN  2-Morpholinocarbonyl, N-(2-methyl-
4-[[4-(acetamidophenyl)methyl]-N-[(2,3-dihydro-
3,4-benzodioxan-6-yl)methyl]-N-(2-methylpropyl)-
ICA INDEX NAME)

```




L3 ANSWER 76 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
pyrimidinyl]thio)methyl]phenyl)- (CA INDEX NAME)




```

320  939778-36-8  CAPLUS
320  Acetanide, N-[4-[[[4-amino-5-cyano-6-(2-furanyl)-2-
pyrimidinyl]thio]methyl]phenyl]- (CA INDEX NAME)

```



R01 939 779-69-7 CAPL08
 C02 Acetanide, N-[4-[[[4-amino-5-cyano-6-(2-thienyl)-2-
 pyridinyl]thio]methoxy]phenyl]- (CA INDEX NAME)



RQ \$39780-47-9 CAPLOS
 CN Acetanilide, N-[4-[[[4-amino-5-cyano-6-(2-thienyl)-2-oxoimidazo[1,2-a]thiazolomethyl]phenyl]- (CA INDEX NAME)

13 ANSWER 76 OF 143 CAPLUS COPYRIGHT 2009 ACS on ETR

ACCESSION NUMBER: 2007:640323 CAPLOS
 DOCUMENT NUMBER: 147:46355
 TITLE: Drugs containing aminocyanopyridine derivatives having adenosine A2A receptor agonistic effects
 INVENTOR(S): Kato, Masahisa; Kato, Noriaki; Okada, Minoru; Ueda

INVENTOR(S): Kato, Masaya; Kato, Norisuke; Okada, Minoru; Uno, Tetsuyuki; Ito, Nobuaki; Takeji, Yasuhiro; Shinohara, Hisashi; Fwua, Masahiro

PATENT ASSIGNER(S): Ohtsuka Pharmaceutical Co., Ltd., Japan

PATENT ASSIGNEE(S): Ohtsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 292pp.

DOCUMENT TYPE:	CODED:
LANGUAGE:	Patent
FAMILY ACC. NUM. COUNT:	Japanese
	1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007145828	A	20070614	JP 2006-293353	20061027
PRIORITY APPL. INFO.:			JP 2005-315444	A 20051027

OTHER SOURCE(S): MARPAT 147:46155



AB The invention provide drugs having adenosine A2A receptor agonistic effects, suitable for use in treatment of eye disease, e.g. glaucoma, wherein the drugs contain compds. represented by a formula 1 (R1 = (un)substituted aryl, heterocyclo; R2 = C3-6 alkyl, lower alkenyl, etc.; R3 = R, lower alkyl, acyl) or their salts as active components. For example, N-[4-(6-amino-5-cyano-2-[6-methylpyrididin-2-ylmethylsulfanyl]pyrimidin-4-yl)phenyl]acetamide


was prepared, and examined for its effect on adenosine A2A receptor *in vitro*, and

IT 939777-50-1P 939778-9C-8P 939779-6B-7P
939780-47-9P 939781-92-7P 939782-87-3P
939783-77-4P

[drugs containing aminocyanopyrrolidine derivs. having adenosine A2A receptor agonistic effects]

	receptor agonistic effects)
RR	939777-50-1 CAPL08
CR	Acetanide, N-[4-[[[4-[4-(acetylamino)phenyl]-6-amino-5-oxo-2-


L3 ANSWER 76 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




```

RN  939781-92-7  CAPLOS
CN  Acetanide, N-[4-[[[4-amino-5-cyano-6-(2-fluorophenyl)-2-
pyrimidinylthio]methyl]phenyl]- (CA INDEX NAME)

```



R2N 939782-87-3 CAPLOS
 CN Acetanide, N-[4-[[[4-amino-5-cyano-6-(4-hydroxyphenyl)-2-
 pyrimidinyl]thio]methyl]phenyl]- (CA INDEX NAME)



HN	939783-77-4	CAPLOS
CN	Acetanide, N-[4-[[[4-amino-5-cyano-6-(3-hydroxyphenyl)-2-	

L3 ANSWER 79 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



93 931291-15-4 CAPLUS
 CH Acetamide, N-[4-(3-methyl-5-(3-oxo-1-phenyl-1H-pyrazol-5-yl)-1H-pyrazol-3-yl)-4-(2,2,2-trifluoroacetyl)phenyl]- (CA INDEX NAME)



93 931291-17-6 CAPLUS
 CH Acetamide, N-[4-(3-methyl-5-(3-oxo-1-phenyl-1H-pyrazol-5-yl)-1H-pyrazol-3-yl)-4-(2,2,2-trifluoroacetyl)phenyl]- (CA INDEX NAME)




REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS

L3 ANSWER 80 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

ACCESSION NUMBER: 2007050128 CAPLUS
 DOCUMENT NUMBER: 1461482074
 TITLE: Preparation of azole heterocyclic compounds as G protein-coupled receptor kinase (GRK) inhibitors
 INVENTOR(S): Kawanishi, Tetsuya; Ohashi, Toshiaki; Hasegawa, Hiroshi; Ogino, Masaki
 PATENT ASSIGNOR(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 175pp.
 DOCUMENT TYPE: OTHER JPO/APP
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: Japanese
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007112789	A	20070510	JP 2006-249474	20060904
PROCHITTY APPL. INFO.			JP 2005-276722	A 20050922
OTHER SOURCE(S):		NOBAPT 146:492074		
GC				



AR The title compounds, [I] R = each (un)substituted amino-lower alkyl, N-containing heterocyclic-lower alkyl, or N-containing heterocyclic; R1 = H, lower alkyl, each (un)substituted amino-lower alkyl, N-containing heterocyclic-lower alkyl, or N-containing heterocyclic; or R and R1 are bonded to each other to form a N-containing heterocyclic ring; ring A = (un)substituted N-containing heterocyclic ring; ring B = (un)substituted aromatic ring; X = H, C-92; R2 = H, halo, each (un)substituted hydroxyl, heterocyclic, NR2, R2, or COR2; NO2, cyano, optionally substituted CO2R, aryl, S = R, each (un)substituted hydroxyl, heterocyclic, or COR2, optionally esterified

CO2R, aryl] or salts thereof are prepared. These compounds are useful as preventive and therapeutic agents of circulatory diseases such as heart failure, hypertension, and arteriosclerosis, etc., based on the potent GRK inhibitory action. Thus, (2S)-2-phenylamino-4-[(tert-butylcarbamoyl)amino]butanoic acid hydrazide underwent cyclization

with 4-cyanopyridine NaOEt in ethanol at 55° for 15 h to give 2-[(tert-butylcarbamoyl)amino]-1-phenylamino-1-[3-(4-pyridyl)-1H-1,2,4-triazol-5-yl]propane which was stirred in concentrated HCl at room temperature for 30 min to give 3-amino-1-phenylamino-1-[3-(4-pyridyl)-1H-1,2,4-triazol-5-yl]propane


L3 ANSWER 79 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 RECORD. ALL CITATIONS AVAILABLE IN THE SE
 FORMAT

L3 ANSWER 80 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

3)]propane trihydrochloride (17). It in vitro inhibited the GRK2-dependent phosphorylation of bovine tubulin with IC50 of 6150 μM. It and 2-amino-1-[5-(chlorophenyl)amino]-1-[3-(4-pyridyl)-1H-1,2,4-triazol-5-yl]ethane trihydrochloride promoted the accumulation of cAMP in HEK293 cells overexpressing human β2 receptor with IC50 of 2.0 and 0.58 μM, resp. Pharmaceutical formulations, e.g. a capsule contg. 17, were prepd.
 IT 935781-32-1P, N-[4-[(4-aminol-4-[3-(4-pyridyl)-1H-1,2,4-triazol-5-yl]piperidin-1-yl)methyl]phenyl]acetamide tri(trifluoroacetate)
 RU RUC (Pharmacological activity); RU Synthesis; preparation; TSP (Therapeutic use); EUGL (Biological study); PREP (Preparation); URES (Uses)
 (preparation of azole heterocyclic compds. as G protein-coupled receptor kinase (GRK) inhibitors for prevention or treatment of circulatory diseases)

93 935781-32-1 CAPLUS
 CH Acetamide, N-[4-[[4-(phenylamino)-4-[3-(4-pyridyl)-1H-1,2,4-triazol-5-yl]-1-piperidinyl]methyl]phenyl]-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)


CH 1
 CHN 935781-31-0
 CHN C27 H29 N7 O



CH 2
 CHN 76-05-1
 CHN C2 H F7 O2




13 ANSWER 85 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




$\text{O}=\text{C}=\text{O}$

BN 932112-27-5 CAPLUS
CN Benzamide, 4-(acetylamino)-N-[[1,6-diethyl-4-[(tetrahydro-2H-pyran-4-ylamino)-3H-pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-hydroxy-




BN 932112-74-8 CAPLUS
CN 3-[3-((4-(acetylamino)-2-ethyl-1H-pyridin-5-yl)methyl)-2-hydroxybenzoyl]amino-4-ethylpyridine-5-ylmethoxybenzoamide- (CA INDEX NAME)

13 ANSWER 85 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




BN 932112-94-2 CAPLUS
CN 3-[3-((4-(acetylamino)-2-ethyl-1H-pyridin-5-yl)methyl)-2-hydroxybenzoyl]amino-4-ethylpyridine-5-ylmethoxybenzoamide- (CA INDEX NAME)




BN 932112-09-2 CAPLUS
CN Benzamide, 4-(acetylamino)-N-[[1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-ylamino)-3H-pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-hydroxy-

13 ANSWER 85 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




BN 932112-75-9 CAPLUS
CN 3-[3-((4-(acetylamino)-2-ethyl-1H-pyridin-5-yl)methyl)-2-hydroxybenzoyl]amino-4-ethylpyridine-5-ylmethoxybenzoamide- (CA INDEX NAME)




BN 932112-84-0 CAPLUS
CN Benzamide, 4-(acetylamino)-N-[[1,6-diethyl-4-[(tetrahydro-2H-pyran-4-ylamino)-3H-pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-hydroxy-

13 ANSWER 85 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



IT 932112-87-0P
BN PAC (Pharmacological activity); BPH (Synthetic preparation); THU (Therapeutic use); BGL (Biological study); PEP (Preparation); USES (Uses)
[Preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases]
BN 932112-87-0 CAPLUS
CN Benzamide, 4-(acetylamino)-N-[[1,6-diethyl-4-[(tetrahydro-2H-pyran-4-ylamino)-3H-pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-methoxy-



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

1.1 RUNNER 26 OF 143 CAPLES COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:351990 CAPLES
DOCUMENT NUMBER: 106:358852
TITLE: Aryl-substituted imidazo[1,2-a]pyridine derivatives
aa

INVENTOR(S): C2a receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy Claffey, Michelle Marie; Goldstein, Steven Wayne; Jung, Stanley; Nabel, Arthur; Sheline, Walker

PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 97pp.
CODING: PXXXXX

DOCUMENT TITLE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

[illegible]

US 2005-718517P P 20050911

OTKAZ SODRUZE (S): NAKPA7 146:358852
01

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

X8 The invention relates to aryl-substituted imidazole, 1,2-pyridines and related compounds. of general formula I, where are antagonists of the mammalian CCR2 receptor. In compounds I, R is H, or 5, or 5 each R is independently selected from CH₃, CH₃, C(CH₃)₂, N(CH₃), N(CH₃)₂, S, and O, where R and R' containing 2 is a heterocyclic group, and R' containing 1-3 heteroatoms independently selected from N, O, and S, and where R1 is independently H, halo, alkyl, alkenyl, alkynyl, aryl, substituted C1-6 alkyl, (un)substituted sulfonyl, (un)substituted C1-10 cycloalkyl, etc., and a bond between two groups S may be a single bond or a double bond; U, V, X, and Y are independently selected from CH, CR, or CN, and where the ring contains no more than two nitrogen atoms; W is CR, or N, R2, R3, and R4

13 ANSWER 87 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:284167 CAPLUS
DOCUMENT NUMBER: 146:337900

TITLE: Preparation of triazole derivatives as Axl inhibitors
INVENTOR(S): Singh, Rajender; Sylvain, Catherine; Bolland, Sacha;
Zhang, Jiang; Partridge, John J.; Clough, Jeffrey
PATENT ASSIGNEE(S): Ricel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 424pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

[illegible]

JP 2009307080 7 20090219 JP 2008-530213 20080907
PRIORITY APPLN. INFO.: US 2005-914673P P 20050907

US 2006-790166P	P	20060307
US 2006-813143P	P	20060612
WO 2006-US34970	W	20060907

OTHER SOURCE(S): MARPAT 146:337900
GT

1.3 ANSWER RE OF 7 CARLOS COPYRIGHT 2009 ACS ON STN (Continued)
independently selected from H, halo, (un)substituted C1-4 alkyl,
(un)substituted C2-6 alkynyl, (un)substituted C3-10 cycloalkyl,
(un)substituted C2-7 acyl, (un)substituted C1-4 alkoxy, carbonyl, ester and
K5 is H or F. The invention also relates to the prepn. of 1,
pharmaceutical compns. comprising a compd. 1 and optionally a
pharmaceutically acceptable carrier, as well as to the use of the compns.
for the treatment of chronic inflammatory diseases including
psoriasis (ps).


in the central nervous system, peripheral nervous system, lungs, and bone joints. Suzuki coupling of 4-bromoisotophene with 3,4-dimethylphenylboronic acid and α - bromination resulted in the formation of bromomethyl ketone II, which underwent heterocyclization with 2-amino-5-bromopyridine to give imidazopyridine III. Coupling of III with $\text{Zn}(\text{CH}_3)_2$ followed by heterocyclization with trimethylsilyl anide gave tetrazolimidazopyridine IV. The compounds of the invention are antagonists of GABA receptors, e.g., compd. IV expressed

17 930599-55-6P, N-(3-Fluoro-4,5-dimethylphenyl)acetanide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PACT
(Reactant or reagent)
[intermediate; preparation of indinavirpyridine derivs. as C3a receptor
antagonists]

FN 930599-55-6 CAPLUS
 CN Acetamide, N-(3-fluoro-4,5-dimethylphenyl)- (CA INDEX NAME)



13 ANSWER 87 OF 143 CAPLOS COPYRIGHT 2009 ACS on STM (Continued)



AB Triazole derivs. I and II [A = CO, CS, COO, CONH and derivs., etc.; R1 = (un)substituted (hetero)aryl, cycloalkyl, etc.; R2, R4, R5 = independently

H, alkyl, aryl, aralkyl, etc.). R3 = (un)substituted aryl, alkyl, cycloalkyl, aralkyl; and their stereoisomers and tautomers, and their pharmaceutically acceptable salts, hydrates, solvates, N-oxides, and prodrugs; with proviso(s) and pharmaceutical compo. containing them are disclosed as inhibitors of the activity of the receptor protein tyrosine kinase Axl. Methods of using triazoles I and II in treating diseases or conditions associated with Axl catalytic activity are also disclosed.

reacting 4-[2-(pyrrolidin-1-yl)ethoxy]aniline with cyanocarbonimidic acid di-Ph ester, followed by cyclization with hydrazine, and acylation with 4-isopropoxybenzoic acid gave acylated triazole III. Selected triazoles


IT 929263-15-OP, 1-[[4-(4-acetylamino)phenyl]carbonyl]-5-amino-3-[(1,4-benzodioxan-6-yl)amino]-1H-1,2,4-triazole

HL: PMC (Pharmacological activity); SYN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of triazole derivs. as Akl inhibitors)

EN 929263-15-0 CAPLOS
CN Acetamide, N-[4-[[5-amino-3-[[2,3-dihydro-1,4-benzodioxin-6-yl]amino]-1H-

1,2,4-triazol-1-yl]carbonyl]phenyl)- (CA INDEX NAME)




L3 ANSWER 89 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RI 927676-14-0 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-5-methoxy- (CA INDEX NAME)



RI 927676-18-6 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3-chloro-5-methylphenyl]methyl]amino]indanemethyl]-5-methoxy- (CA INDEX NAME)



RI 927676-19-7 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-5-methoxy-2-methyl- (CA INDEX NAME)




RI 927676-19-5 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-6-fluoro- (CA INDEX NAME)

L3 ANSWER 89 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RI 927676-19-8 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-6-fluoro- (CA INDEX NAME)



RI 927676-42-4 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-6-fluoro- (CA INDEX NAME)




RI 927676-43-5 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-6-fluoro-2-methyl- (CA INDEX NAME)




RI 927676-44-6 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-7-fluoro-2-methyl- (CA INDEX NAME)


L3 ANSWER 89 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RI 927676-11-1 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-5-fluoro- (CA INDEX NAME)



RI 927676-32-2 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-5-(phenylmethyl)- (CA INDEX NAME)



RI 927676-34-4 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-5-hydroxy- (CA INDEX NAME)



RI 927676-36-6 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-5-(phenylmethyl)- (CA INDEX NAME)

L3 ANSWER 89 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RI 927676-45-7 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-5-cyano- (CA INDEX NAME)



RI 927676-46-8 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-5-cyano-2-(1,1-dimethylethylamino)carboxyl- (CA INDEX NAME)



RI 927676-47-9 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-5-cyano-2-(1,1-dimethylethylamino)carboxyl- (CA INDEX NAME)



RI 927676-47-9 CAPLUS
CN 18-Indole-3-acetamide, N-[[[4-(acetylamino)-3,5-dichlorophenyl]methyl]amino]indanemethyl]-5-cyano-2-(1,1-dimethylethylamino)carboxyl- (CA INDEX NAME)

IT 927676-31-30 927676-32-00 927676-33-00
927676-49-19 927676-50-49 927676-50-20
927676-40-49
RI: RCT (Reactant); RPI (Synthetic preparation); RPP (Preparation); RAC (Reactant or reagent)
Preparation of indoleacetic acid acyl guanidines as β -secretase

11	APPROX 92 OF 100	CAPLUS COPYRIGHT 1999 ACE on 97th
ACCESSION NUMBER:	2007:174109	CAPLUS
DOCUMENT NUMBER:	146125962	
TITLE:	Novel salt forms of vildagliptin for therapeutic use	
INVENTOR(S):	Robert, Jean-Louis; Villhauer, Edwin Bernard	
PATENT ASSIGNEE(S):	Novartis AG, Switzerland; Novartis Pharma GmbH	
SOURCE:	PCT Int. Appl., 59pp.	
	CODING: PEXK22	
DOCUMENT TYPE:	Patent	
LANGUAGE:	English	
FAMILY ACQ. NUM. CONCERN:	1	
PATENT INFORMATION:		

The present invention relates to novel salts of
 18-1-(12-hydroxy-1-adamantylamino)acetyl-2-cyano-pyrrolidine
 (IAF237, vildagliptin) and a pharmaceutically acceptable acid in a 1:1
 stoichiometry. The salts are in crystalline, partially crystalline,
 amorphous or polymorphic forms. Thus, 13.0 g of IAF237 was treated with 4.88 g of
 fumaric acid in ethanol at 50°C to afford vildagliptin hydrogen
 fumarate (yield 17.10 g, 93.1%). The salt showed improved stability
 compared to vildagliptin base.
 KCl: PEP (Properties); SM (Synthesis preparation); TS (Therapeutic use
 NCI (Biological study); PEP (Preparation); USES (Uses)

```

1  ANUMBA 93 OF 143 CAPUSU COPYRIGHT 2009 ACS on STM
2  ACCESSION NUMBER: 2007.61234 CAPUSU
3  DOCUMENT NUMBER: 15128461
4  TITLE:
5      Preparation of an arolopyridines as inhibitors of
6      gusA protein kinase.
7  INVENTOR(S):
8      Inoue, Takayuki; Tojo, Takashi; Morita, Masataka;
9      Nakaya, Yutaka; Tanaka, Tetsuo; Shirakami, Shobei;
10     Sakaki, Hiroshi; Tanaka, Akihiro; Takahashi, Fumio;
11     Miyoshi, Koichiro; Shimizu, Tadayuki; Shimoto,
12     Akiro; Honda, Takashi; Sawada, Hiroshi
13     Aetela's Pharma Ind., Japan
14  PATENT ABSTRACT(S):
15  SOURCE:
16
17  DOCUMENT TYPE:
18  LANGUAGE:
19  FAMILY ACC. NUM. COUNTRY:
20
21  PCT Int. Appl., 350pp
22  COMBID: P12342
23  Patent
24  English
25

```


OTHER SOURCE(S): MARPAT 146:184461
QI

```

L3 ANEMER 22 OF 143 CAPLUS COPYRIGHT 1989 ACS ON STN (Continued)
      (prepn. and stability of vildagliptin salt forms for treatment of
      neurodegenerative/cognitive, metabolic and other disorders)
EN 924666-96-4 CAPLUS
CN Benzoic acid, 4-(acetylamino)-, compd. with
      [2-(2-[(2-hydroxytricyclo[3.3.1.12,7]dec-1-ylamino)acetyl]-2-
      pyridylideneazobenzonitrile [1:1] (CA INDEX NAME)
CN 1
CEN 274901-16-5
CNF C17 H25 N3 O2

```

Absolute stereochemistry. Rotation (-).



CN	2
CEH	554-08-1
CNP	C9 H9 N O2




L3 ANSWER 93 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN |Continued



IT	920964-25-6P	920965-49-7P	
	Hc: PAC (Pharmacological activity); SYN (Synthetic preparation); THU (Therapeutic use); BGL (Biological study); PREP (Preparation); USES (Uses) [preparation of as anoloprylidine as inhibitors of JAK3 (james protein kinase)]		
FIN	920964-25-6	CAPLMS	
CH	Acetamide, N-[4-[(1R)-3,3,6-dihydro-2-oxoimidazo[4,5-c]pyrrolo[2,3-b]imidazol-1(2H)-yl]-5-methylidene]carbamoylphenyl-, (S)- [INDRE NAME]		


Absolute stereochemistry.



IN 920965-49-7 CAPLUS
 CN Acetanide, N-[4-[(2,6-dihydro-1-[(1R,2S)-2-methylcyclohexyl]-2-oxoimidazo[4,5-d]pyrrolo[2,3-b]pyridin-3(2H)-yl)methyl]-2-thiazolyl]-N-[4-methylphenyl]-, rel- (CA INDEX NAME)
 Relative stereochemistry.

10/562,112


13 ANSWER 93 of 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



13 ANSWER 94 of 143 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007-54858 CAPLUS
 DOCUMENT NUMBER: 146114282
 TITLE: Preparation of diamine compounds as agricultural fungicides
 INVENTOR(S): Niki, Toshiyuki Saito, Hirohisa, Mikioka, Masanori
 PATENT ASSIGNER(S): Nissan Chemical Industries, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 2006, C08B1:7800AF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. CONT: 1
 PATENT INVENTOR(S):

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007009914	A	20070118	JP 2005-316878	20051026
PRIORITY APPL. INFO.			JP 2004-316467	A 20041017
			JP 2005-15076	A 20050505
			JP 2005-153397	A 20050531
			JP 2005-154406	A 20050531


OTHER SOURCE(S): MARPAT 146114282
 GI




AB The title compds. with general formula of Ar1-C(Ra)-C(Rb)-C(R1)-R(R2)-C(R3)-Ar2 [wherein R1 and R2 = independently H or alkyl; R4 and R5 = H; R3 and R6 = independently H or alkyl with exclusion of R3 = H; Ar1 and Ar2 = independently (un)substituted Ph or heterocyclop; Ra and Rb = independently halogen, cyano, etc.; R1 and R2 = independently O or S] or salts thereof are prepared as agricultural fungicides. Thus, the compound I was prepared in a multi-step synthesis. Some of the invention compds. showed good fungicidal activities against phytopathogenic fungi.
 IT 514815-35-55
 RL AG: (Agricultural use); BPP (Biological study, unclassified); SPS (Synthetic preparation); BSC (Biological study); PREP (Preparation);
 UNES (Uses)
 (fungicide; preparation of diamine compds. as agricultural fungicides)

13 ANSWER 94 of 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 RI 913483-33-0 CAPLUS
 CH Benzenecarboxamide, 6-(acetylamino)-4-[(1S)-2-methyl-1-[[[4-methylbenzoyl]amino]propyl]-1H-imidazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



13 ANSWER 95 of 143 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006131218 CAPLUS
 DOCUMENT NUMBER: 146229213
 TITLE: New route to the 5,12-dihydro-7H-benzo[2,1-b:3,4-b']indole-6-one
 AUTHOR(S): Henry, Nicolas; Elin, Jerome; Benetean, Valerie; Mercet, Jean-Yves
 CORPORATE SOURCE: Institut de Chimie Organique et Analytique, UMR CNRS 6005, Université d'Orléans, Orléans, 45067-2, Fr.
 SOURCE: Synthesis (2006), (12), 3955-3961
 CDBI: SYNTH; ISSN: 0039-7881
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146229213
 GI




AB A new route to the paulone scaffold was designed. The key step consisted in a free radical indole formation from an o-alkenyl arylacrylonitrile followed by Stille coupling with N-Boc-o-iodoaniline. After deprotection and closure of the seven-membered ring by intramolecular, parent or cyano-substituted paulones, e.g., 1 R = H or CH3, were obtained in moderate to good yields.
 IT 524627-26-95 924627-31-6P
 RL RCT (Reactant); SPS (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 UNES (Uses)
 (preparation of benzazepanobenzolone derivs. via tin-mediated Fukuyama radical indole cyclization of o-alkenyl arylacrylonitriles followed by palladium-catalyzed Stille coupling with N-Boc-iodoanilines as key steps)
 RI 924627-26-9 CAPLUS
 CH Formamide, N-(4-cyano-2-iodophenyl)- (CA INDEX NAME)



RI 924627-33-4 CAPLUS
 CH 2-Propanoic acid, 3-[5-cyano-2-(formylamino)phenyl]-, methyl ester (CA INDEX NAME)

L3 ANMER 99 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANMER 99 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2004125258 CAPLUS
 DOCUMENT NUMBER: 1461703
 TITLE: Preparation of diarylsulfonamide and their use as secreted frizzled related protein-1 modulators for bone disorders such as osteoporosis
 INVENTOR(S):
 OFFICEY: Curtis; Michael, Albert; John; Chai; Mengxiao; Weinaker; Gregory; Scott; Milson; Nathan; Ailing; Krishnamurthy; Chris; Conners; Thomas; Joseph; Webb; Michael; Ryan; Woodworth; Richard P.; Waply; John, and Brother Ltd., USA
 PCT Int. Appl., 516pp.
 COINT: F33255

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006124875	A2	20061113	WO 2004-051886	20040512
WO 2006124875	A3	20070118		
M: AU, AG, AL, AM, AT, AY, AZ, BA, BB, BG, BF, BH, BI, BJ, BR, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GR, GU, HE, GM, GW, HP, HU, ID, IL, IN, JP, KE, KG, KM, KN, KR, KP, KZ, LA, LG, LI, LU, LV, LY, MC, MD, ME, MG, MK, MN, MU, MW, MY, NA, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TN, TR, TT, TZ, UA, US, UZ, VC, VE, VG, VI, VN, YU, ZA, ZM, ZW				
NM: AT, BG, BR, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, GU, HE, HU, ID, IL, IN, JP, KE, KG, KM, KN, KR, KP, KZ, LA, LG, LI, LU, LV, LY, MC, MD, ME, MG, MK, MN, MU, MW, MY, NA, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TN, TR, TT, TZ, UA, US, UZ, VC, VE, VG, VI, VN, YU, ZA, ZM, ZW				
CF, CG, CI, CN, CO, CU, DE, EE, ES, FI, FR, GB, GR, GU, HE, HU, ID, IL, IN, JP, KE, KG, KM, KN, KR, KP, KZ, LA, LG, LI, LU, LV, LY, MC, MD, ME, MG, MK, MN, MU, MW, MY, NA, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TN, TR, TT, TZ, UA, US, UZ, VC, VE, VG, VI, VN, YU, ZA, ZM, ZW				
US 2006027644	A1	20061107	US 2004-437788	20040510
US 2006247334	A1	20061127	US 2004-247334	20040512
CA 2467234	A1	20061123	CA 2004-246736	20040512
EP 1879859	A2	20060103	EP 2004-779425	20040512
FI, AT, BG, BR, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, GU, HE, HU, ID, IL, IN, JP, KE, KG, KM, KN, KR, KP, KZ, LA, LG, LI, LU, LV, LY, MC, MD, ME, MG, MK, MN, MU, MW, MY, NA, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SM, SN, SV, TH, TN, TR, TT, TZ, UA, US, UZ, VC, VE, VG, VI, VN, YU, ZA, ZM, ZW				
JP 2005440579	T	20051130	JP 2003-114770	20020512
IN 2002000024	A	20050617	IN 2002-088624	20021107
NO 2007005781	A	20060205	NO 2007-5781	20071112
NO 2007014240	A	20060207	NO 2007-14240	20071112
KR 2008022363	A	20060311	KR 2007-729136	20071113
CN 101208912	CN	20060620	CN 2004-00067300	20071127
PRIORITY APPL. INFO.:				
US 2004-437788 A US 20040510				
WO 2004-051886 W 20040512				

OTHER SOURCE(S):

01

NABAT 146:7703

L3 ANMER 99 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



AS Title compd. 7 [R] = (un)substituted Ph, naphthyl, pyridinyl, pyrrolidyl, indolyl, etc.; R' = O, or an electron pair; R2 = R, perfluoroalkyl, alkoxy, halo, etc.; R4 = R, halo, perfluoroalkyl, alkoxy, or R2C(R4) = 5-7 membered (un)substituted cycloalkyl; R5, R6 = independently R, perfluoroalkyl, aryl, alkoxy, halo, R7, R8 = independently R, (un)substituted cycloalkyl, alkylaryl, heterocycloalkyl, etc., or R2C(R7) = (un)substituted 5-6 membered heterocycloalkyl, with the exception of specified groups, and their pharmaceutically acceptable salts] were prepared as modulators of secreted frizzled related protein-1 (SFRP-1). These, reacting 4-isopropylbenzenesulfonyl chloride with benzene in the presence of AlCl3.

Followed by chlorosulfonation of diaryl sulfone with chlorosulfonic acid and treatment of 2-(phenylethyl)amine with sulfonyl chloride gave benzenesulfonamide II (no data for the intermediates). In a fluorescence polarization binding assay, sulfonamide II displayed affinity for SFRP-1 (IC50 = 0.3 μM). In a cell-based assay, selected 1 were inhibitors of SFRP-1. It and their pharmaceutical forms, are useful for treating a variety of disorders, including osteoporosis.

IT 915759-39-0; N-[4-[[[15-(2-methyl-5-phenylsulfonyl)phenyl]sulfonyl]amino]piperidin-1-yl]carbamoyl]phenyl]acetamide 915759-76-1P; N-[4-[[[15-(2-methyl-5-phenylsulfonyl)phenyl]sulfonyl]amino]piperidin-1-yl]carbamoyl]phenyl]acetamide
 R1a PAC (Pharmacological activity); SFR (Synthetic preparation); T80 (Toxicity assay); R2C (Biological study); P800 (Preparation); U800 (Use)


(drug candidate) preparation of diarylsulfonamide and their use as secreted frizzled related protein-1 modulators

CN 915759-39-0 CAPLUS

CN Acetamide


N-[4-[[[15-(2-methyl-5-phenylsulfonyl)phenyl]sulfonyl]amino]-1-piperidyl]carbamoyl]phenyl- (CA INDEX NAME)

L3 ANMER 99 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RU 915759-76-1 CAPLUS

CN Acetamide, N-[4-[[[15-(phenylsulfonyl)-2-((11-(fluorenyl)phenyl)sulfonyl]amino)-1-piperidyl]carbamoyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT:

6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANMEK 104 of 143 CARLOS COPYRIGHT 2009 ACS on STM (Continued)
[Acetyl,Pro2]NPT is anesthetized rats, 3 mg/kg ITI administered orally reduced the blood pressure by approx 30 mm hg after 1.5 h. 1 are useful for treating diseases characterized by elevated neuropeptide Y activity such as obesity, and abnormal food behavior, and for controlling food intake


IT 912943-81-8P, 4-[[Acetyl]](2-piperidin-1-yl)ethyl]amino]-8-[5-[4-[3-[[1-ethylpropyl]oxy]ureido]-2-methoxyphenyl]thiazol-2-yl]benzamide
912943-85-3P, 4-[[Acetyl]](2-piperidin-1-yl)ethyl]amino]-8-[4-[4-[3-[[1-ethylpropyl]oxy]ureido]phenoxy]-2-methylphenyl]benzamide
912944-48-0P, 4-[[Acetyl]](3-piperidin-1-yl)propyl]amino]-8-[4-[4-[3-[[1-ethylpropyl]oxy]ureido]phenoxy]-2-methylphenyl]benzamide
912944-89-3P, 4-[[Acetyl]](3-piperidin-1-yl)propyl]amino]-8-[5-[4-[3-[[1-ethylpropyl]oxy]ureido]-2-methoxyphenoxy]thiazol-2-yl]benzamide
912944-70-0P, 4-[[4-[[Acetyl]](2-piperidin-1-yl)ethyl]amino]-8-[5-[4-[3-[[1-ethylpropyl]oxy]ureido]-2-methoxyphenoxy]thiazol-2-yl]benzamide

diethylamino)propyl]amino]benzoyl]amino]phenoxy]-5-[3-[[1-ethylpropyl]oxy]ureido]-2-methylbenzamide

RE: PAC (Pharmacological activity); STM (Synthetic preparation); TSD (Toxicological use); RICH (Biological study); PREP (Preparation); USDB (Index NAME)


(drug candidate) preparation of NPT antagonists and their use for treating obesity, and abnormal food behavior and for controlling food intake)

RE 912943-81-8 CARLOS
CN Benzamide, 4-[[acetyl]](2-[1-piperidyl]ethyl]amino)-8-[5-[4-[[[1-ethylpropyl]amino]carbonyl]amino]-3-methylphenyl]- (CA INDEX NAME)




RE 912943-85-2 CARLOS
CN Benzamide, 4-[[acetyl]](3-[1-piperidyl]ethyl]amino)-8-[4-[4-[[[1-ethylpropyl]amino]carbonyl]amino]phenoxy]-3-methylphenyl]- (CA INDEX NAME)

L3 ANMEK 104 of 143 CARLOS COPYRIGHT 2009 ACS on STM (Continued)



RE 912944-70-8 CARLOS
CN Benzamide, 2-[[4-[[[4-[[acetyl]](3-[[diethylamino]propyl]amino]benzoyl]amino]phenoxy]-5-[[[1-ethylpropyl]amino]carbonyl]amino]-8-methyl]- (CA INDEX NAME)




IT 912947-86-3P, 4-[[Acetyl]](2-piperidin-1-yl)ethyl]amino]benzoic acid 912947-90-1P, 4-[[Acetyl]](3-piperidin-1-yl)propyl]amino]benzoic acid 912947-94-5P, Ethyl 4-[[Acetyl]](3-piperidin-1-yl)propyl]amino]benzoate 912947-96-7P, 4-[[Acetyl]](3-diethylamino)propyl]amino]benzoic acid 912948-03-9P, Methyl 4-[[Acetyl]](3-diethylamino)propyl]amino]benzoate

RE: NCT (Neutamin); STM (Synthetic preparation); PREP (Preparation); NACT (Neutamin or Neutamin)


(intermediate) preparation of NPT antagonists and their use for treating obesity, and abnormal food behavior and for controlling food intake)

RE 912947-86-5 CARLOS
CN Benzoic acid, 4-[[acetyl]](2-[1-piperidyl]ethyl]amino)- (CA INDEX NAME)



L3 ANMEK 104 of 143 CARLOS COPYRIGHT 2009 ACS on STM (Continued)


PAGE 3-A



PAGE 3-B

—CH₂—

RE 912944-48-0 CARLOS
CN Benzamide, 4-[[acetyl]](3-[1-piperidyl]propyl]amino)-8-[4-[4-[[[1-ethylpropyl]amino]carbonyl]amino]phenoxy]-3-methylphenyl]- (CA INDEX NAME)




PAGE 3-B

—CH₂—


RE 912944-69-5 CARLOS
CN Benzamide, 4-[[acetyl]](3-[1-piperidyl]propyl]amino)-8-[5-[4-[4-[[[1-ethylpropyl]amino]carbonyl]amino]-2-methoxyphenoxy]-2-thiazolyl]- (CA INDEX NAME)

L3 ANMEK 104 of 143 CARLOS COPYRIGHT 2009 ACS on STM (Continued)


RE 912947-90-1 CARLOS
CN Benzoic acid, 4-[[acetyl]](3-[1-piperidyl]propyl]amino)- (CA INDEX NAME)




RE 912947-94-5 CARLOS
CN Benzoic acid, 4-[[acetyl]](3-[1-piperidyl]propyl]amino)-, ethyl ester (CA INDEX NAME)



RE 912947-96-7 CARLOS
CN Benzoic acid, 4-[[acetyl]](3-[1-piperidyl]propyl]amino)-, methyl ester (CA INDEX NAME)



RE 912948-03-8 CARLOS
CN Benzoic acid, 4-[[acetyl]](3-[1-piperidyl]propyl]amino)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

10/562,112

L3 ANSWER 105 OF 143 CAPLOS COPYRIGHT 2009 ACS ON STN (Continued)



RI 911574-96-4 CAPLOS
 CH Benzoic acid, 2-(1-(4-(acetylamino)-3-methoxyphenyl)-2-(trifluoromethyl)phenyl)ethyl ester (CA INDEX NAME)
 Double bond geometry as shown.



RI 911571-51-0 CAPLOS
 CH Hydratizincbenzoyle acid, 2-(1-(4-(acetylamino)-3-methoxyphenyl)-2-(trifluoromethyl)phenyl)ethyl ester (CA INDEX NAME)



RI 911571-51-2 CAPLOS
 CH Hydratizincbenzoyle acid, 2-(1-(4-(acetylamino)-3-methoxyphenyl)-2-(trifluoromethyl)phenyl)ethyl ester (CA INDEX NAME)

L3 ANSWER 106 OF 143 CAPLOS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

SALN:

PATENT ASSIGNER(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009


JANUARY 2009

JANUARY 2009

JANUARY 2009

JANUARY 2009


L3 ANSWER 105 OF 143 CAPLOS COPYRIGHT 2009 ACS ON STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE AS

FORMAT

L3 ANSWER 106 OF 143 CAPLOS COPYRIGHT 2009 ACS ON STN (Continued)




AB The title compds. I [ring A = (un)substituted aryl, (un)substituted heteroaryl; ring B = benzene ring or thiophene ring; ring C = benzene ring, 5- to 7-membered aliphatic hydrocarbon ring; R1 = halo, (un)substituted hydrocarbon group, (un)substituted heteroaryl, etc.; R2 = halo, alkyl, heteroalkyl, etc.; n = 0-4; R3 = H51851, H18711, H187475, etc.; further details on R3 are given; R51, R52 = H, (un)substituted alkyl, (un)substituted heteroaryl, etc.; R71, R74 = H, alkyl; R75 = H, alkyl, heteroaryl, etc.; a proviso is given] are prepared. Thus, 3-(3-(1,3-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-oxoprop-1-yl)-N-(1-methoxyethyl)benzenesulfonamide was prepared in 2 steps from 1-(3,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazol-2-ylidene)ethanone and 3-(1-methoxyethyl)benzenesulfonamide. In an assay for gonadotropin-releasing hormone (GnRH) receptor antagonism, compds. of this invention showed IC50 values of 0.056 nM to 0.24 nM.

IT 911581-50-32
 RU PAC (Pharmacological Activity); RU (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

Preparation of dihydrobenzimidazole moiety-containing propano-1,3-dione derivative
 as GnRH receptor antagonists

RI 911581-50-3 CAPLOS
 CH Benzamide, 4-(acetylamino)-N-[2-[[1-(3,5-difluorophenyl)-2-(3-[[1-(1-methoxyethyl)amino]ethyl]phenyl]-2-oxoethylidene)]-2,3-dihydro-2H-benzimidazol-1-yl]] (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE AS

FORMAT

L3 ANSWER 106 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

L3 ANSWER 107 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 20041057923 CAPLUS
 DOCUMENT NUMBER: 1461245741
 TITLE: Utilization of aminophenone derivatives in technology
 INVENTOR(S): Levine, Howard L.; Rolopova, William J.; De Biegler, Danielle
 PATENT ASSIGNER(S): Columbia Laboratories, Inc., USA
 SOURCE: New; 11pp
 CDBN: RU03CA
 DOCUMENT TYPE: Patent
 LANGUAGE: Romanian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 1240415	B1	2004-08-10	RU 1999-777	1999-07-07
PRECEDENT APPL. INFO.:			RU 1999-777	1999-07-07

OTHER SOURCE(S): MARPAT 1461245741
 AS The invention relates to a novel utilization of aminophenone derivs. in technol., for treating infestations with epinephrine tonic substances. According to the invention, the utilization of aminophenone derivs. is made administering them i.m., this being an administering way allowing quick installation of the antiods effect, or orally, thus allowing a

long term effect, useful in preventing the neurotoxications with epinephrine products.
 IT 925411-59-2
 RI: T80 (Therapeutic use); B10L (Biological study); U8S (Uses)
 Utilization of aminophenone derivs. in technol.)

RU 925411-59-2 CAPLUS
 CN Antanador, N-[4-(2,4-dimethyl-5-oxocyclohexyl)phenyl]- (CA INDEX N09M)



L3 ANSWER 108 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 20041051249 CAPLUS
 DOCUMENT NUMBER: 1461397152
 TITLE: Preparation of pyrimidinones and triazinones as prokinetins 1 (PK1) receptor antagonists.
 INVENTOR(S): Costa, Steven J.; Spitzke, Alexey B.; He, Wei; Liaka, Joseph; Ralovsky, Janet L.; Schultz, Mark J.
 PATENT ASSIGNER(S): Janssen Pharmaceutice, N.V., Belg.; Milwaukee, Tamara,
 SOURCE: A, PCT Int. Appl., 17pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200414715	A1	20041005	WO 2004-059613	20040314
W: AU, AG, AL, AM, AT, AU, BE, BR, BG, BY, CA, CH, CN, CO, CZ, DE, DK, EA, EP, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, MG, MK, MN, MU, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, SP, SV, SW, TH, TR, TW, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
NW AT, BE, BR, CH, CN, DE, DK, ES, FI, FR, GB, GR, HU, IE, JP, KR, KZ, MG, MK, MN, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, SP, SV, SW, TH, TR, TW, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
AU 2004229793	A1	20041005	AU 2004-229793	20040314
CA 2402576	A1	20041005	CA 2004-260256	20040314
US 20040235018	US	20041019	US 2004-274167	20040314
EP 1464230	A1	20041213	EP 2004-738649	20040314
X: AT, BE, BG, CH, CN, DE, DK, ES, FI, FR, GB, GR, HU, IE, JP, KR, KZ, MG, MK, MN, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, SP, SV, SW, TH, TR, TW, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
JP 2004534502	T	20040928	JP 2004-530345	20040314
MX 2007121849	A	20040120	MX 2007-11849	20070924
IN 20070027398	A	20040125	IN 2007-0027398	20071009
KR 20040024544	KR	20040116	KR 2007-724515	20071004
CN 101246169	A	20041217	CN 2004-80017800	20071122
PRECEDENT APPL. INFO.:			WO 2004-059613	P 20040314


OTHER SOURCE(S): MARPAT 1461397152
 OI

L3 ANSWER 109 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

AS Title compds. [I: A1 = R, (substituted) aryl, heteroaryl, cycloalkyl, heterocyclyl; A2 = (substituted) (CH2)2; CH2CH2(CH2)2; s = 1-5; t = 1-2; X = O, S; D = DMS; when A2 = R, P = (CH2)4-6; when A2 = H, P = CH2; CH2CH2, CH2CH2CH2, A2 = R, (substituted) benzodioxolyl, heteroaryl, cycloalkyl; Ph = N, CH2, R = H, alkyl; L2 = pyridyl, piperidinyl, etc.; Q = CH2CH2, s = 0, 1; G = C(=O)N(CH2)2, R = H, R = (substituted) alkyl, alkoxy, alkyl; R = H, (substituted) alkyl, alkyl, alkoxy, cycloalkyl, aryl, heteroaryl, etc.; R2 = atoms to form a 5-8 membered (one-substituted) ring with protons), were prepared Thus, N-[2-[4-(4-methylphenyl)-1-(4-methylphenyl)-4,6-dioxo-1,4,5,6-tetrahydro-1,3,5-triazin-2-ylamino]ethyl]pyrimidinone (preparation free of 4-methylphenylthiourea, N-ethoxycarbonyl isopropate, 4-ethylphenyl alc., ethylenediamine, and pyrazole-1-carboxamide given) inhibited PDE in a Gq2 mobilization assay with IC50 = 0.058 μM.
 IT 910113-64-59 910113-64-59
 RI: P4C (Pharmacological activity); S8N (Synthetic preparation); T8U (Therapeutic use); B10L (Biological study); P2EP (Preparation); U8S (Uses)
 (claimed compound; preparation of pyrimidinones and triazinones)
 AS prokinetins 1 receptor antagonists
 RU 910113-64-59 CAPLUS
 CN Antanador, N-[4-[1-[4-(4-amino-2-methylamino)ethyl]amino]-3,4-dihydro-2,4-dioxo-3-phenylmethyl]-1,3,5-triazin-1(2H)-yl]methylphenyl]- (CA INDEX N09M)


IT 910113-64-59 910113-64-59
 RI: P4C (Pharmacological activity); S8N (Synthetic preparation); T8U (Therapeutic use); B10L (Biological study); P2EP (Preparation); U8S (Uses)
 (claimed compound; preparation of pyrimidinones and triazinones)
 AS prokinetins 1 receptor antagonists
 RU 910113-64-59 CAPLUS
 CN Antanador, N-[4-[1-[4-(4-amino-2-methylamino)ethyl]amino]-3,4-dihydro-2,4-dioxo-3-phenylmethyl]-1,3,5-triazin-1(2H)-yl]methylphenyl]- (CA INDEX N09M)

RU 910113-64-59 CAPLUS
 CN Antanador, N-[4-[1-[4-(4-amino-2-methylamino)ethyl]amino]-3,4-dihydro-2,4-dioxo-3-phenylmethyl]-1,3,5-triazin-1(2H)-yl]methylphenyl]- (CA INDEX N09M)



RU 910113-64-59 CAPLUS
 CN Antanador, N-[4-[1-[4-(4-amino-2-methylamino)ethyl]amino]-3,4-dihydro-2,4-dioxo-3-phenylmethyl]-1,3,5-triazin-1(2H)-yl]methylphenyl]- (CA INDEX N09M)

L3 ANSWER 109 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE XS

FORMAT

L3 ANSWER 109 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 2004.1031178 CAPLUS
 DOCUMENT NUMBER: 145.419138
 TITLE: Preparation of 3-benzylpyrrolidin-2-one and N-benzylpyrrolidin-2-one derivatives as prophyllactoferric agents for diabetes
 INVENTOR(S): Choy, Mahoney Kasai, Shirose, Tanashita, Toshio
 PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
 SOURCE: PCT Int. Appl., 742pp.
 CUBRID: P2426
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY KEY: NUM. COUNTR: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 20041042190	A1	20041005	WO 2004-IP307462	20040311
W1, AU, AC, AL, AM, AT, BE, BG, BR, CA, CH, CN, CO, CU, DE, DK, EP, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, KZ, LG, LU, LV, LY, MA, MC, MD, ME, MG, MK, MN, MU, NL, NO, NZ, PA, PE, PG, PH, PL, PT, RU, SE, SI, SK, SM, ST, SV, TH, TR, TT, UA, US, VE, VN, YU, ZA, ZM, ZW				
WM, AT, BE, BG, CH, CY, CZ, DE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, LV, MC, NL, NO, NZ, PL, PT, RU, SE, SI, SK, SM, ST, SV, TH, TR, TT, UA, US, VE, VN, YU, ZA, ZM, ZW				
EP 1864973	A1	20031212	EP 2004-731350	20040331
W1, AT, BE, BG, CH, CY, CZ, DE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, LV, MC, NL, NO, NZ, PL, PT, RU, SE, SI, SK, SM, ST, SV, TH, TR, TT, UA, US, VE, VN, YU, ZA, ZM, ZW				
PRIORITY APPL. INFO.: JP 2005-102913	A	20050120		
			WO 2004-IP307462	W 20040331

OI




AB 11β-hydroxysteroid dehydrogenase 1 inhibitors comprising compounds represented by the formula (1) or salts thereof or prodrugs of the compounds.

L3 ANSWER 109 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 on the side [X] = (un)substituted cyclic group; R1 = H, (un)substituted cyclic group; X = H, CH3, C2-6, substituent; L1, L2 = a bond, (un)substituted bivalent aliph. hydrocarbon group, -(alkyl)-P-(alkyl) group, amide, (un)substituted C1-6 alkylene; n, n = 0, 1; Y = O, S, SO, SO2, SR4, SO2SR4, SR4SR4; R4 = H, (un)substituted C1-6 alkyl; ring A = (un)substituted 6- to 7-membered heterocyclic ring optionally fused to a ring) are disclosed. These compounds have an excellent inhibitory activity against 11β-hydroxysteroid dehydrogenase 1 and are useful as prophyllactoferric agents for diabetes, insulin resistance, obesity, lipid metabolic abnormality, hypertension, or arteriosclerosis. Thus, 2 M lithium diisopropylamide/THF (1.32 M, 1.32 M) was added to a soln. of 0.50 g 1-(2-methylbenzyl)pyrrolidin-2-one in 10 mL THF at -78° and the resulting mixt. was stirred for 10 min. The resulting soln. was treated with a soln. of 0.50 g 1-(2-methylbenzyl)pyrrolidin-2-one in 5 mL THF, stirred at -78° for 10 min, and warmed to room temp. to give, after workup and silica gel chromatog., 80% 3-(1-(2-methylbenzyl)-1-(2-methylbenzyl)pyrrolidin-2-one (11). 1-(2-methylbenzyl)-7-(1-(2-methylbenzyl)pyrrolidin-2-one (11) is a prep. from 1-(cyclohexyl)pyrrolidin-2-one and 2,6-trichlorotoluene) showed IC50 of 7.3 nM against of human 11β-hydroxysteroid dehydrogenase 1. A tablet comprising a tablet formulation compg. the compd. 11 were described.

IT 911718-46-IP 911718-47-IP 911720-12-IP
 911722-99-IP 911724-42-IP 911725-09-IP
 911729-10-IP
 K1a P4C (Pharmacological activity); S8H (Synthetic preparation); T8U (Therapeutic use); B10L (Biological study); P8P8 (Preparation); U8S8 (Case);
 (preparation of 3-benzylpyrrolidin-2-one and N-benzylpyrrolidin-2-one
 deriva. as 11β-hydroxysteroid dehydrogenase 1 inhibitors and prophyllactoferric agents for diabetes)

AB 11β-hydroxy-7-(1-(2-methylbenzyl)pyrrolidin-2-one (11) is a prep. from 1-(cyclohexyl)pyrrolidin-2-one and 2,6-trichlorotoluene) showed IC50 of 7.3 nM against of human 11β-hydroxysteroid dehydrogenase 1. A tablet comprising a tablet formulation compg. the compd. 11 were described.

Absolute stereochemistry.



AB 11β-hydroxy-7-(1-(2-methylbenzyl)pyrrolidin-2-one (11) is a prep. from 1-(cyclohexyl)pyrrolidin-2-one and 2,6-trichlorotoluene) showed IC50 of 7.3 nM against of human 11β-hydroxysteroid dehydrogenase 1. A tablet comprising a tablet formulation compg. the compd. 11 were described.

Absolute stereochemistry.


L3 ANSWER 109 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

AB 11β-hydroxysteroid dehydrogenase 1 inhibitors comprising compounds represented by the formula (1) or salts thereof or prodrugs of the compounds.




AB 11β-hydroxysteroid dehydrogenase 1 inhibitors comprising compounds represented by the formula (1) or salts thereof or prodrugs of the compounds.

AB 11β-hydroxysteroid dehydrogenase 1 inhibitors comprising compounds represented by the formula (1) or salts thereof or prodrugs of the compounds.



AB 11β-hydroxysteroid dehydrogenase 1 inhibitors comprising compounds represented by the formula (1) or salts thereof or prodrugs of the compounds.

L1 ANIML2 110 OF 143 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

13 NUMBER 111 OF 143
 ACCESSION NUMBER: 1606.977348 CAPLOS
 DOCUMENT NUMBER: 145-156-79
 TITLE: Preparation of imidazo[1,5-a]pyridines as GFG
 inhibitors, particularly selective b-PGF antagonists,
 and 5-enoylpyruvate inhibitors for treatment of cancer
 and cardiovascular diseases
 INVENTOR(S): Goffio, Chantal; Goffio, Alain; Bosny, Francoise;
 Bordes, Marie-Francoise
 PATENTY ASSIGNEE(S): Sanofi-Aventis, Fr.
 SOURCE: Int. Appl., 1992.
 DOCUMENT TYPE: OTHER: PILED
 LANGUAGE: French
 FAMILY AC. NUM. COUNT: 1
 PATENT INFORMATION:

[illegible]

OTHER SOURCE(S): NARPAT 145:356779
(3)

13 ANSWER 113 OF 143 CHAPTER COPYRIGHT 2009 ACS on STM (Continued)



AS Tatic compds. I [R = a substituent on the pyridine ring selected from H, halo, alkyl, OR and deriva., NEt and deriva., benzoyloxy, etc.; R1 = H, halo, alkyl, (un)substituted NR, inosyrally, etc.; R2, R3 = independently OR and deriva., etc. COMMON to all: 6-nitro, 4-nitro, 5-nitro, 6-methoxy, and their salts, and their hydrates and solvates] were prepared as acidic fibroblast growth factor (a-FGF) and basic fibroblast growth factor (b-FGF) inhibitors, especially b-FGF antagonists and angiogenesis inhibitors.


For example, reacting imidazo[2,3-a]pyridine with 3-methoxy-4-nitrobenzoyl chloride in 1,2-dichloroethane in the presence of TEA gave imidazopyridine

12 In p. = 1973. I inhibited the growth of b-FGF- or a-FGF-expressing tumor cell lines (HVEFC) with a specific activity in the range of 10^{-9} M to 10^{-5} M. I exhibited a specific activity in the range of 10^{-11} M to 10^{-7} M in an angiogenesis test in vitro. I am active by oral administration of doses of 0.1 to 50 mg/kg. Thus, I am useful for treatment of cancer, certain cardiovascular diseases, diabetic retinopathy, chronic inflammations, obesity, macular degeneration, hypo-


IT 910094-46-2P 910094-94-9P,
2-[3-[3-Methoxy-4-(propenylamino)benzoyl]imidazo[1,3-a]pyridin-1-yl]benzoic acid sodium salt
RL: PAC (Pharmacological activity); SYN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Case)

	(drug candidate; preparation of imidazopyridines as P3F inhibitors)
RN	910094-89-2 CAPLUS
CN	Benzoic acid, 3-[3-[3-methoxy-4-[(1-oxopropyl)amino]benzoyl]imidazo[1,5-a]pyridin-3-yl]-, ethyl ester (CA INDEX NAME)

L3 ANSWER 111 OF 143 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)




RN 910094-94-9 CAPLUS
 CN Benzoic acid, 3-[3-[3-methoxy-4-[(1-oxopropyl)amino]benzoyl]imidazo[1,5-
 a]pyridin-3-yl]-, sodium salt (1:1) (CA INDEX NAME)



IT 910095-07-7, Methyl 2-[3-[3-methoxy-4-(propionylamino)benzoyl]imidazo[1,5-a]pyridin-1-yl]benzoate
EL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazopyridines as EGE inhibitors)

RXN 910095-07-7 CAPLUS
 CN Benzoic acid, 3-[3-[3-methoxy-4-[(1-oxopropyl)amino]benzoyl]imidazo[1,5-
 a]pyridin-3-yl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


13 ANSWER 115 OF 143 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)
 * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compound 1 [A, Ar = independently (un)substituted hetero/aryl, cycloalkyl, heterocyclyl; L = a bond, CO, NH, COOH, NHO, NHO, NH-CO-NH, etc.; one of X, Y and Z = H, NO, and the other of Y, T and S = CH₃, CH₃, H; R₁, R₂ = independently H, halo, CN, CH, alkyl, etc.) were prepared as kinase inhibitors for treatment especially of cancer. Thus, pyrazolo[1,4-b]pyridine 11 was prepared via Suzuki coupling of iodide

111 or its tri-tert-butyl analog with arylpyridineborane IV, and one pot two-step synthesis/cyclization in DMF in the presence of TFA containing 10% sodium. The pyrazolo[4,3-c]pyridine analog inhibited PAK, KDR and Tie2 kinases with an IC50 of 75 nM, 33 nM, and 5 nM, resp. Thus, I and their pharmaceutical novelties, are useful as antitumor agents (no detail).

17 90063-42-3P, N-[2-[[[4-(3-amino-1H-pyrazolo[4,3-c]pyridin-4-yl)phenyl]ureido]-4-(trifluoromethyl)phenyl]acetamide 90063-44-TP 90063-47-CP
 RI: PAK (Pharmacological activity); STN (Synthetic preparation); TSP (Therapeutic use); RCL (Biological study); PREP (Preparation); USES (Uses)
 (Drug candidate) preparation of pyrazolopyridines as PAK, KDR and Tie2 kinase inhibitors and their use for treating cancer


32 90063-42-3 CAPLOS
 CN Acetamide, N-[2-[[[4-(3-amino-1H-pyrazolo[4,3-c]pyridin-4-yl)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




32 90063-44-7 CAPLOS
 CN Acetamide, N-[2-[[[4-(3-amino-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

13 ANSWER 115 OF 143 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)
 RI: RCT (Reactant); STN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate) prep. of pyrazolopyridines as PAK, KDR and Tie2 kinase inhibitors and their use for treating cancer

32 90063-43-5 CAPLOS
 CN Acetamide, N-[2-[[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




32 90063-45-8 CAPLOS
 CN 1,1,2-Hydroxy-1,1-dimethyl-2-oxo-2-(4-[[[4-[[[2-(acetamido)-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-3-cyano-2-pyridinyl]-1,1,2-tris(1,1-dimethylethyl) ester (CA INDEX NAME)




32 90063-46-9 CAPLOS
 CN 1,1,2-Hydroxy-1,1-dimethyl-2-oxo-2-(4-[[[4-[[[2-(acetamido)-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-3-cyano-2-pyridinyl]-1,1,2-tris(1,1-dimethylethyl) ester (CA INDEX NAME)

13 ANSWER 115 OF 143 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)




32 90063-47-0 CAPLOS
 CN Acetamide, N-[2-[[[4-(3-amino-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-pyridinyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




17 90063-43-6P, N-[2-[[[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ureido]-4-(trifluoromethyl)phenyl]acetamide 90063-45-8P 90063-46-3P 90063-48-3P, N-[2-[[[5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]amino]carbonyl]amino]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


13 ANSWER 115 OF 143 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)



32 90063-48-1 CAPLOS
 CN Acetamide, N-[2-[[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



17 90063-48-2, N-[2-[[[5-(2-bromopyridin-2-yl)ureido]-4-(trifluoromethyl)phenyl]acetamide 90063-49-2P 90063-49-3P, N-[2-[[[5-bromo-2-pyridinyl]amino]carbonyl]amino]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)
 (intermediate) prep. of pyrazolopyridines as PAK, KDR and Tie2 kinase inhibitors and their use for treating cancer



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

10/562,112


L3 ANSWER 116 OF 143 CARLUS COPYRIGHT 2009 ACS ON STM (Continued)

DOCUMENT NUMBER: 2006-634421 CARLUS
 145125333
 TITLE: Preparation of substituted pyrrolidiones as renin inhibitors
 INVENTOR(S): Heilmann, Werner; Cottens, Sylvain; Ehrhardt, Claus; Janssen, Edgar; Leuthaus, Edwige; Liliane; Janssen, Malin; Janssen, Klaus; Kottmann, Wilfried; Sallner, Wolfgang; Simic, Oliver
 PATENT ASSIGNER(S): Novartis A. S., Delft; Novartis Pharma G.S.B.H.
 SOURCE: PCT Int. Appl. 455 pp.
 DOCUMENT TYPE: OTHER: P10020
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNTRY: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006064986	A2	20060629	WO 2005-EP13786	20051221
WO 2006064986	A3	20060821		
W1	Ad, Al, Am, At, Au, Az, Ba, BB, BS, Bu, BW, Br, BE, CA, CH, CN, CO, CP, CY, CZ, DE, DK, DM, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, MA, MD, ME, MG, MK, MN, MU, MY, NL, NO, NZ, OM, OS, PA, PE, PG, PH, PL, PT, PY, RE, RU, SA, SG, SI, SK, SL, SM, SN, SV, SW, TH, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW			
BM, AT, BS, BR, CH, CT, CE, DE, ES, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, MA, MD, ME, MG, MK, MN, MU, MY, NL, NO, NZ, OM, OS, PA, PE, PG, PH, PL, PT, PY, RE, RU, SA, SG, SI, SK, SL, SM, SN, SV, SW, TH, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
AD 2005131892	AI	20060629	EP 2005-21892	20051221
CA 2389351	A1	20060629	CA 2005-2389351	20051221
EP 1836163	AP	20050928	EP 2005-825434	20051221
JP 2005135586	AP	20050928	JP 2005-144739	20051221
IN 20071264446	A	20070824	IN 2007-08446	20070611
KL 2007027772	A	20070808	KL 2007-7772	20070622
PE 200708806	A	20070829	PE 2007-71674	20070720
SI 12111715	A	20070830	SI 2007-804743	20070807
FI000777 APPL. INFO. 1	CH	2004-08260	A	20041223
		WO 2005-EP13786	W	20051221

OTHER SOURCE(S): MARIAT 145103533
 CI

L3 ANSWER 116 OF 143 CARLUS COPYRIGHT 2009 ACS ON STM (Continued)



AB The invention is related to the preparation of 3-mono-, 3,4-di-, and 3,4,4-trisubstituted pyrrolidone isomers of formula I [I] = (un)substituted aryl, cycloalkyl, mono- or bicyclic heterocycyl, etc.; R2 = (un)substituted aryl, cycloalkyl, aryl, etc.; R3 = H, (un)substituted aryl/cycloalkyl, aryl, etc.; R4 = H, OR1 = a bond, OR2, OR3, OR4, etc.; or R3C14 = (un)substituted ring annealed to an (un)substituted aryl, heterocycyl or cycloalkyl; or R3 and R4 together with L = -CH2SO-

IMINO: 7 - CR2, CR2 mono-substituted by alkyl, C6, C6r with protons; and their


SA: their pharmacological formulations and their use in the diagnostic and therapeutic treatment of a disease that depends on inappropriate activity of renin. Thus, rel-11 was prepared by amidation of rel-(10,43)-3,4-dibenzopyrrolidine-3-carboxylic acid with diphenylamine, reduction of the amide, and N-debenzylation. I inhibited renin with IC50 values in the range of 10 nM to 20 µM in various *in vitro* tests.

IT 895242-95-2P
 RI: RAC (Pharmacological activity); RH (Synthetic preparation); TH (Therapeutic use); RICE (Biological study); PREP (Preparation); USES (Uses)

IN: (renin inhibitor preparation of pyrrolidones as renin inhibitors)

RH 895242-95-2 CARLUS
 CN Carboxylic acid, 1-[4-[acetylaminophenyl]methyl]-, (3R,4R)-4-[(16-methoxy-3-(3-methoxypropoxy)phenyl)oxymethyl]pyrrolidin-2-yl-3-pyrrolidinyl ester, rel-1 (9C1) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNTRY: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 117 OF 143 CARLUS COPYRIGHT 2009 ACS ON STM (Continued)


L3 ANSWER 117 OF 143 CARLUS COPYRIGHT 2009 ACS ON STM (Continued)

DOCUMENT NUMBER: 2006-630242 CARLUS
 145103563
 TITLE: Preparation of piperidine derivatives as antagonists of the CC chemokine receptor CCR3 and their use as anti-inflammatory agents
 INVENTOR(S): Arns, Daniel O.; Chow, Yu-Ling; Kochany, Monica J.; Lee, Wansueng; Lu, Shou-Pei; Mengel, Anne; Phillips, Gary Wei; Gao, Feng-Yu; Hongyi
 PATENT ASSIGNER(S): Schering-Plough AG, Germany
 SOURCE: PCT Int. Appl., 230 pp.
 DOCUMENT TYPE: OTHER: P10020
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNTRY: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006064988	A1	20060629	WO 2005-EP13938	20051220
W1	Ad, Al, Am, At, Au, Az, Ba, BB, BS, Bu, BW, Br, BE, CA, CH, CN, CO, CP, CY, CZ, DE, DK, DM, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, MA, MD, ME, MG, MK, MN, MU, MY, NL, NO, NZ, OM, OS, PA, PE, PG, PH, PL, PT, PY, RE, RU, SA, SG, SI, SK, SL, SM, SN, SV, SW, TH, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW			
BM, AT, BS, BR, CH, CT, CE, DE, ES, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, MA, MD, ME, MG, MK, MN, MU, MY, NL, NO, NZ, OM, OS, PA, PE, PG, PH, PL, PT, PY, RE, RU, SA, SG, SI, SK, SL, SM, SN, SV, SW, TH, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
US 20060187844	A1	20060727	US 2005-205322	20051219
EP 1908829	A1	20060611	EP 2005-824154	20051220
JP 2005244154	A	20050710	JP 2005-244154	20051220
JP 2005244154	A	20050710	JP 2005-244154	20051220
FI000777 APPL. INFO. 1	CH	2004-08260	A	20041223
		WO 2005-EP13938	W	20051220

OTHER SOURCE(S): CASREACT 145103563; MARIAT 145103563
 CI

L3 ANWEM 117 of 143 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)



AB Title compds. represented by the formula I [wherein Ar = Ph, pyridinyl, isooquinolyl; R1 = H, halo, cycloalkyl, etc.; R2 = a bond, O, S, NR(R'), NR(R')CO or C(R)(R'); R3 = (un)substituted alkyl or alkenyl; R4 = CO, COO, CN, C(R) or a bond; R5 = independently R, oxo, (halo)alkyl, etc.; R6 = CO, CN, C(R)(R'), etc.; R7 = independently R, halo, cycloalkyl, etc.; R8 = independently R, (halo)alkyl, aryl, etc.; R = (un)substituted Ph or 2-thienyl; and enantiomers, diastereomers, tautomers, salts, solvates and radiolabeled analogs thereof] were prepared as CC chemokine receptor CCR1 antagonists. For example, II was provided in a multi-step synthesis starting from 1-[5-(chloro-2-hydroxyphenyl)urea], I and their pharmaceutical salts, etc. used for the treatment of inflammatory disorders, such as multiple sclerosis, leukoencephalopathy, and etc.

IT 894770-46-3p, H-[2-(4-fluorophenyl)methyl]-1-piperidinyl]-2-oacetoxy-4-methylphenyl]acetamide 894770-47-9p, H-[2-(4-cyano-4-[(4-fluorophenyl)methyl]-1-piperidinyl]-2-oacetoxy-4-methylphenyl]acetamide

AI, PKC (Pharmacological activity); SPN (Synthetic preparation); THO (Therapeutic use); BCL (Biological study); PREP (Preparation); USBS (Uses)

[preparation of substituted piperidine derivs. as antagonists of CC chemokine receptor CCR1 and their use as anti-inflammatory agents]

AB 894770-46-3 CAPLOS
CN Acetamide, H-[2-(4-cyano-4-[(4-fluorophenyl)methyl]-1-piperidinyl]-2-oacetoxy-4-methylphenyl]- (CA INDEX NAME)

L3 ANWEM 118 of 143 CAPLOS COPYRIGHT 2009 ACS on STN

20091578147 CAPLOS

141612907

Preparation of heterocyclic derivatives as histone deacetylase inhibitors

Nitsch, Barbara; Perrigo, Federico; Jones, Philip; Imperio, Raffaele; Kinnel, Olaf; Llauger, Rudi

Ontario, Ontario, Jesus Maria; Pesatore, Giovanna; Newley, Michael; Scarpelli, Elias; Schella, Carsten

Istituto di Ricerche di Biologia Molecolare P.

Angeli, S.p.A., Italy

PCT Int. Appl., 215 pp.

CODEN: PAKADZ

Patent

English

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P


P

P

P

P


L3 ANWEM 117 of 143 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)



AB Title compds. I [R = (NR')C(R)(R')R'; R' = O, S, N; R = (CH2)q, q = 1-4; R = a bond, O, S, NR(R'), NR(R')CO or C(R)(R'); R' = (un)substituted alkyl or alkenyl; R2 = a bond, O, S, NR(R'), NR(R')CO or C(R)(R'); R3 = (un)substituted alkyl or alkenyl; R4 = CO, COO, CN, C(R) or a bond; R5 = independently R, oxo, (halo)alkyl, etc.; R6 = CO, CN, C(R)(R'), etc.; R7 = independently R, halo, cycloalkyl, etc.; R8 = independently R, (halo)alkyl, aryl, etc.; R = (un)substituted Ph or 2-thienyl; and enantiomers, diastereomers, tautomers, salts, solvates and radiolabeled analogs thereof] were prepared as CC chemokine receptor CCR1 antagonists. For example, II was provided in a multi-step synthesis starting from 1-[5-(chloro-2-hydroxyphenyl)urea], I and their pharmaceutical salts, etc. used for the treatment of inflammatory disorders, such as multiple sclerosis, leukoencephalopathy, and etc.

IT 894770-47-9 CAPLOS

CN Acetamide, H-[2-(4-cyano-4-[(4-fluorophenyl)methyl]-1-piperidinyl]-2-oacetoxy-4-methylphenyl]- (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANWEM 118 of 143 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)

20091578147 CAPLOS

141612907

Preparation of heterocyclic derivatives as histone deacetylase inhibitors

Nitsch, Barbara; Perrigo, Federico; Jones, Philip; Imperio, Raffaele; Kinnel, Olaf; Llauger, Rudi

Ontario, Ontario, Jesus Maria; Pesatore, Giovanna; Newley, Michael; Scarpelli, Elias; Schella, Carsten

Istituto di Ricerche di Biologia Molecolare P.

Angeli, S.p.A., Italy

PCT Int. Appl., 215 pp.

CODEN: PAKADZ

Patent

English

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P

P


P

P

LI	ANMER 120 of 143	CARLOS	COFFREY 2009 ACS on STN
	ACCESSION NUMBER:	2006:495991	CARLOS
	DOCUMENT NUMBER:	145:0161	
	TITLE:	Preparation of heterocyclic derivatives as selective androgen receptor modulators (SRAMs)	
	INVENTOR(S):	Zhang, Hongyue Li, Xiaojing Sui, Zhuhua	
	PATENT ASSIGNEE(S):	Zhang, Hongyue Li, Xiaojing Sui, Zhuhua	
	SOURCE:	PAT Int. Appl., 234 pp.	
	DOCUMENT TYPE:	CODES: P1600	
	LANGUAGE:	Patent	
	FAMILY ACC. NUM. COUNT:	English	
	PATENT INFORMATION:	1	

OTHER SOURCE(S): CASREACT 145:8161; NAKPAT 145:8161
OT

13 ANNEX 120 OF 143 CATION. COPYRIGHT 2009 ACS on STM (Continued)



AB Title compds. I [W = O, S, NH and derivs.; R1 = halo/alkyl; R2 = H, carbosyl/halo/alkyl, etc.; D = (CH₂)_n; n = 0-1; B = (un)substituted Ph, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl; A = (un)substituted 3,4-dihydro-2H-pyrazolyl, 4,5-dihydro-3H-pyrazolyl, 4,5-dihydrooxazol-3-yl, etc.; or pharmaceutically acceptable salts] were prepared as selective androgen receptor modulators (SARMs). Thus.

N-(4-cyano-1-trifluoromethylphenyl)-2-methylacrylamide with 4-fluoro-1-(phenylmethyl)benzenecarboxylchloride gave dihydrogynazole II. Selected I was active in the ventral prostate and levator ani weight and in the ventral prostate and seminal vesicle weights in

vivo assays. Therefore, I and pharmaceutical compns. thereof are useful for the treatment of disorders and conditions modulated by androgen receptor, such as prostate carcinoma, benign prostatic hyperplasia and

DATE: 10/10/2001

IT 1005309-04-1
BL: BCT (Boatant); BCT (Boatant or Boatant)

```
(preparation of heterocycle derivs. as selective androgen receptor
```

```
modulators)
```

Q20 Acetanide, N-[4-(2-oxoethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

13 ANSWER 129 OF 143 CAPSULE COPYRIGHT 2009 MCS on STM (Continued)

10/562,112

L3 ANSWER 121 of 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 ACCESSION NUMBER: 20061349352 CAPLUS
 DOCUMENT NUMBER: 145147552
 TITLE: Chemical Development of SD9331: Synthesis of a Bromomethylquinazolinone Avoiding a Nonspecific Radical Bromination
 AUTHOR(S): Bentley, Dagnez, Geoffrey, Andrew A.; Warren, Kenneth S. H.
 COORDINATE SOURCE: Process Research and Development Department, AstraZeneca, Macclesfield, Cheshire, SK10 2BA, UK
 SOURCE: CORDIS; ORCID; ISSN: 1083-6160
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CHEMAB 14547552
 AB An efficient regioselective synthesis of SD9331 5-bromo-3-methylquinazolinone (70M) has been accomplished via SD9331 Quinazolinone HCl avoiding a nonspecific bromination. The original route used a radical bromination on a substrate with three Me groups, which generated a range of bromomethyl derived compounds that oxidized through to the final active pharmaceutical ingredient (API). A strategy, based on the Simm reaction, was developed to synthesize the required bromomethyl compound in a regioselective manner. This approach was successfully scaled to manufacture a ton of material.
 IT SD9006-36-9P SD9006-37-20
 Reagents: HCl (Reagent); HBr (Synthetic preparation); HBr (Preparation); HBr (Reagent or reagent)
 Chemical development of SD9331 via a bromomethylquinazolinone avoiding a nonspecific radical bromination
 SD SD9006-36-9 CAPLUS
 CH Acetanilide, N-[4-[(acetyloxy)methyl]-3-methylphenyl]- (CA INDEX NAME)



SD SD9006-37-0 CAPLUS
 CH Acetanilide, N-[4-[(acetyloxy)methyl]-2-bromo-3-methylphenyl]- (CA INDEX NAME)

L3 ANSWER 122 of 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 ACCESSION NUMBER: 20061312177 CAPLUS
 DOCUMENT NUMBER: 145124592
 TITLE: 2-Pyrindinyl-N-aryl-7-oxa- or phosphoric ester group benzylamine derivative, preparation and application thereof
 INVENTOR(S): Lin, Long; Chen, Jie; Wang, Hua; Tang, Qinghong; Peng, Wei; Jia, Dehan; Wang, Guochao; Lin, Gang
 PATENT ASSIGNEE(S): Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, P.O. Box 1350, Shanghai 200032, China
 SOURCE: CORDIS; ORCID
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COMPT: 1
 PATENT INFORMATION: 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 CN 1746143 A 20060935 CN 2005-10029355 20050902
 CN 102321979 C 20080101 CN 2005-10029355 20050902
 PRIORITY APP. NO. INFO. 1
 OTHER SOURCE(S): NARPAT 145124592
 GI






AB The 2-pyrindinyl-N-aryl-7-oxa- or phosphoric ester group benzylamine derivative I (D and/or E = halo, Cl-4 alkyl, or Cl-4 haloalkyl); R = H, halo, or Cl-4 alkyl; R1 = CN or di(Cl-4 alkyl)phosphoryl; R2 = H or Cl-4 acyl; R3 = H, ureido, halo, carbonyl, Cl-10 alkyl ester group, haloalkenyl ester group, amido, aminoalkyl, sulfonamido; Cl-4 alkyl, Ph, or Cl-4 alkylphenyl; and X' = R, Cl-4 alkyl, or halo) is prepared by condensation condensation acid derivative with 2-pyrindinylbenzylamine derivative and NaOH in solvent in the presence of NaHCO3 at room temperature-reflux temperature for 0.5-12 h and then esterification with alc. or phenol derivative in organic solvent in the presence of DCC condensing agent and 4-dimethylaminopyridine catalyst at room temperature for 4-24 h. The benzylamine derivative can be prepared by condensation reaction of salicylaldehyde with aniline derivative in organic solvent in the presence of

L3 ANSWER 123 of 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 REFERENCE COMPT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RS



L3 ANSWER 124 of 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)
 ACCESSION NUMBER: 20061312177 CAPLUS
 DOCUMENT NUMBER: 145124592
 TITLE: 2-Pyrindinyl-N-aryl-7-oxa- or phosphoric ester group benzylamine derivative, preparation and application thereof
 INVENTOR(S): Lin, Long; Chen, Jie; Wang, Hua; Tang, Qinghong; Peng, Wei; Jia, Dehan; Wang, Guochao; Lin, Gang
 PATENT ASSIGNEE(S): Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, P.O. Box 1350, Shanghai 200032, China
 SOURCE: CORDIS; ORCID
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COMPT: 1
 PATENT INFORMATION: 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 CN 1746143 A 20060935 CN 2005-10029355 20050902
 CN 102321979 C 20080101 CN 2005-10029355 20050902
 PRIORITY APP. NO. INFO. 1
 OTHER SOURCE(S): NARPAT 145124592
 GI





AB Analise acid derivative, I [X = CH2 or CH2CH2; Y = NH, CH2, or O; R = unsubstituted alkyl, (CH2)3-4-cycloalkyl, -aryl, or -heterocyclyl; R1 = R or alkyl or CH3 = cycloalkyl; R2 = any group given for R, as aryl or sulfonyl group; R3 = (un)substituted (hetero)aryl; R4, R5, R6, R7, R8, R9, R10, R11, R12 = H, any group given for R, halo, sulfonylamine, arylamine, cyano, carbonyl, nitro, etc., or R4a' or R5a' = o- or p- or combine to form halo, R6 and R7 form an alkylidene or alkylphenyl bridge] or their pharmaceutically-acceptable salts were prepared for the treatment of diseases such as obesity and diabetes. Thus, compound II was prepared

via peptide coupling reactions in solution

II 1064450-18-5 1064452-80-7

R1: PPE (Propagator)

[Substituted piperidines as modulators of the melanocortin receptors]

AB 1064450-18-5 CAPLUS

CH INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

and analogs as fattyacyltransferase inhibitors
Wang, Wen-De; Curtin, Michael L.; Fakhoury, Stephen A.; Switney, Stephen L.; Harwood, Lisa A.; Hutchins, Charles W. Li, Qun; Liu, Nan-Ning; Helton, Lisa; Taka, Jennings; O'Connor, Steve; Shan, King L.; Sullivan, Gerard M.; Wang, Gary T.; Wang, Kilo USA

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY AC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	FILED DATE	APPLICATION NO.	DATE
US 2002019527	AL 20020214	US 2001-042791	20020425
PROCTER & GAMBLE, INC.	US 2002-020439	P 20020417	

OTHER SOURCE(S):

GI



AB Title compd. (I) was prepared. Thus, 3-Methoxy-2-methyl-1H-imidazole (preparation each given) and the product O-arylated to give title compound II. Data for biol. activity of I were given.


II 1102368-27-6 1102368-27-6

R1: PPE (Propagator)

[Preparation of (imide)alkylbiphenylcarboxonitriles and analogs as fattyacyltransferase inhibitors]

AB 1102368-27-6 CAPLUS


CH Acetamide, N-[4-[[[4-cyano-3-(1-naphthalenyl)phenyl]-3-pyridyl]amino]methyl]phenyl]- (CA INDEX NAME)



AB 1064450-18-5 CAPLUS


CH INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE SE

FORMAT




AB 1102366-75-5 CAPLUS

CH Acetamide, N-[4-[[[4-cyano-3-(1-naphthalenyl)phenyl]methyl]-3-pyridyl]amino]methyl]phenyl]- (CA INDEX NAME)



AB 1102368-04-6 CAPLUS

CH Acetamide, N-[4-[[[4-cyano-3-(1-naphthalenyl)phenyl]-5-thiazolyl]methyl]amino]methyl]phenyl]- (CA INDEX NAME)




AB 1102369-27-6 CAPLUS

CH Acetamide, N-[4-[[[4-cyano-3-(1-naphthalenyl)phenyl]methyl]-5-thiazolyl]methyl]amino]methyl]phenyl]- (CA INDEX NAME)

10/562,112


L3 ANSWER 133 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



L3 ANSWER 134 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2001565019 CAPLUS
 135152797
 TITLES: Preparation of isothiazolocarboxylic acid derivatives
 and their use as microbicides
 INVENTOR(S): Fukuoka, Yoshinori; Ishikawa, Keiichi; Sawada,
 Haruhiko
 PATENT ASSIGNEE(S): Araki, Yasuo; Asanuma, Letz
 Nihon Bayco Agrochem K. K., Japan
 SOURCE: JCI Int. Appl., 215 pp.
 CDBR: FIDAL2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICANT NO.	DATE
WO 2002055134	A2	20020402	MO 2003-EP482	20030113
WI AU, AG, AM, AT, AU, AZ, BA, BB, BE, BF, BG, CA, CH, CN, CO, CU, DE, DK, EE, ES, FI, GB, GR, HU, IE, IL, IN, JP, KR, LV, LU, MD, ME, MG, MK, MN, MU, MY, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TH, TR, TT, UA, US, VE, VN, YU, ZA, ZW				
IN: GB, GR, HU, IE, IL, IN, JP, KR, LV, LU, MD, ME, MG, MK, MN, MU, MY, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TH, TR, TT, UA, US, VE, VN, YU, ZA, ZW				
JP 200213869	A	20020607	JP 2000-19309	20000110
JP 1841592	A2	20021004	JP 2001-90747	20010113
RU, AT, BE, CH, DE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, SF, CZ, CY, CU, CL, CM, CR, CA, CN, CO, CU, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, JP, KR, LV, LU, MD, ME, MG, MK, MN, MU, MY, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TH, TR, TT, UA, US, VE, VN, YU, ZA, ZW				
BR 2001007056	A	20040106	BR 2001-7096	20010113
JP 200405010	T	20040219	JP 2001-560303	20010113
US 2003076477	A2	20030310	US 2002-187248	20020715
PRIORITY APPL. INFO. 1			JP 2000-19309	A 20000110
OTHER SOURCE(S):			MANPAT 135-152797	
GI				



AB Title compds. [I] A = R, R₁ = Cl-4-alkyl, Cl-6-alkoxyalkyl, Ph, HOC(CH₂)₂ Q = CH₂, HOC(CH₂)₂, C(CH₃)₂ R₂ = R, Cl-4-alkyl, Cl-6-alkoxyalkyl, C-9-alkoxyalkyl, phenoxymethyl; R₃ = aryl, Cl-4-alkyl, Cl-6-alkoxyalkyl.


L3 ANSWER 134 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)
 Cl-4-alkoxy, phenoxy, benzoyloxy, cyano, oxydimethylamino, naphthyl
 one oxygen, or at least one nitrogen and one sulfur, H₂AB₂, CH₂, S(O)₂, F(O)₂ (CH₂)₂; R₄ = G, Cl-4-alkyl, benzyl, Ph, tetraol-3-yl-thiomethyl; R₅

= formyl, Cl-4-alkylthioethyl, Cl-4-alkylthioethyl, phenylthioethyl; R₆ = R, Cl-4-alkyl, Cl-6-alkoxyalkyl, benzyl; R₇ = Cl-4-alkyl, benzyl, Ph, tetraol-3-yl, benzoyl; R₈ = G, I, J; R₉ = Cl-4-alkyl, are prepd. as macrobicides. Title compds. are mixed with extenders and/or surface-active agents in microbicidal compns. and are applied to the macroorganisms and/or to their habitat. Thus, the title compd. II was prepd. and biol. tested for spray effect against *Pyricularia oryzae* in seedling of paddy rice.

2T 1059323-11-1 1059323-74-6 1059326-65-8
 MA 1998 (Froggett)


as Preparation of isothiazolocarboxylic acid derivatives and their use as macrobicides

20 1059323-11-1 CAPLUS
 CH 5-isothiazolocarboxamide, 3,4-dichloro-N-[[[formyl(4-methylphenyl)amino]methyl]- (CA INDEX NAME)




20 1059323-74-6 CAPLUS
 CH 5-isothiazolocarboxamide, N-[[[amyl(4-methylphenyl)amino]methyl]-3,4-dichloro- (CA INDEX NAME)

L3 ANSWER 134 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



20 1059326-65-8 CAPLUS
 CH 5-isothiazolocarboxamide, N-[[[amyl(4-methylphenyl)amino]methyl]-3,4-dichloro-9-methyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE IE FORMAT

13 ANSWER 116 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

1102618-58-9 1102618-56-9 1102618-57-0
 1102618-58-1 1102618-60-5 1102618-61-4
 1102618-62-7 1102618-61-8 1102618-64-9
 1102618-66-2


N/A: PMP (Propionate)

(Organic nitrile derivatives and their use as pesticides)

RN 1102618-70-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102618-73-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102618-74-6 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RN 1102618-75-7 CAPLUS


13 ANSWER 116 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RN 1102618-78-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102618-80-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102618-83-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



13 ANSWER 116 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102618-76-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102618-77-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RN 1102618-78-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 116 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

RN 1102618-80-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102618-81-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102618-82-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RN 1102618-83-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RI 1102640-74-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RI 1102640-75-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RI 1102640-76-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RI 1102640-77-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RI 1102640-78-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RI 1102640-79-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RI 1102640-43-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RI 1102640-44-4 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RI 1102640-45-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RI 1102640-43-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RI 1102640-44-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.




RI 1102640-45-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



RI 1102640-44-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.




RI 1102640-47-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.




RI 1102640-48-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



RI 1102640-49-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.




RI 1102640-50-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.




RI 1102640-51-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



RI 1102640-53-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.




RI 1102640-54-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.




RI 1102640-55-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



RI 1102640-56-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.




RI 1102640-57-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.




RI 1102640-58-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 Double bond geometry as shown.


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



HN 1102658-27-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102658-28-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102658-29-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)




HN 1102658-32-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.



HN 1102658-34-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102658-35-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102658-36-5 CAPLUS


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



HN 1102658-30-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102658-31-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102658-32-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



HN 1102658-37-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102658-38-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102658-39-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.

13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102658-40-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102658-41-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102658-42-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102658-44-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102658-45-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102658-46-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102658-43-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102658-44-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102658-45-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102658-49-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102658-50-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.




HN 1102658-51-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1102618-52-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102618-13-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102618-14-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1102618-55-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102618-16-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102618-57-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1102618-58-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102618-60-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102618-41-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 136 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1102618-62-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102618-63-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.



HN 1102618-44-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


L3 ANMERK 136 OF 143 CAPULUS COPYRIGHT 2009 ACS ON STN (Continued)



NN 1102648-44-1 CAPULUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



REFERENCE COPY:

6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

L3 ANMERK 137 OF 143 CAPULUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 1999-919754 CAPULUS

DOCUMENT NUMBER: 111159733

TITLE: Organic nitride derivatives and their use as

pesticides

INVENTOR(S): Hall, Roger Graham; Steiger, Arthur; Huter, Oskar
Franz, Paul; Alfons, Rüdiger; Kist, Nikolaus; Traub, Stephan
Nöcker, A.; Deitz, J.; Nöcker, A.; Nöcker, A.

PATENT ASSIGNMENT(S): Verwaltungs-gesellschaft m.b.H.

SOURCE: ECT Int. Appl., 49 pp.

CLASS: F102G

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29


PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29

PRIORITY DATA: 1999-04-29


PRIORITY DATA: 1999-04-29

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102548-13-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102548-14-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102548-17-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102559-70-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102559-71-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102559-72-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102562-44-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




HN 1102562-48-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102562-49-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




HN 1102562-46-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


HN 1102562-47-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




HN 1102562-48-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102562-49-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102562-50-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102562-11-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102562-12-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102562-13-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102562-17-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102562-18-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102562-19-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102562-16-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102562-15-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102562-14-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102562-40-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102562-41-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.




HN 1102562-42-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.


13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1102562-43-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102562-44-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102562-45-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1102562-49-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102562-10-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102562-77-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1102562-46-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102562-47-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102562-48-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1102562-72-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102562-74-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102562-75-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



HN 1102562-76-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102562-77-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102564-03-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



HN 1102565-82-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102565-83-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102568-10-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



HN 1102565-79-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102565-80-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102565-81-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



HN 1102568-11-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102568-12-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102568-13-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102568-16-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102568-15-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102568-16-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102568-16-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102568-21-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102568-22-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102568-17-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102568-18-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102568-19-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102568-23-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




HN 1102568-24-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102568-25-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RD 1102568-34-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RD 1102568-37-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RD 1102568-38-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RD 1102568-39-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RD 1102568-39-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RD 1102568-39-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RD 1102568-39-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RD 1102568-39-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RD 1102568-36-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RD 1102568-36-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RD 1102568-32-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RD 1102568-33-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RD 1102568-37-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RD 1102568-37-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RD 1102578-38-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RD 1102578-39-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102579-40-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102579-41-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102579-41-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102579-43-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102579-44-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102579-45-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102579-46-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




HN 1102579-41-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102579-46-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


HN 1102579-49-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




HN 1102579-50-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102579-51-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102579-52-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RR 1102579-43-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RR 1102579-44-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RR 1102579-45-4 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RR 1102579-46-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RR 1102579-47-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RR 1102579-48-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RR 1102579-56-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RR 1102579-57-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RR 1102579-58-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RR 1102579-62-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RR 1102579-63-4 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.




RR 1102579-64-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.


13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1102579-63-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102579-64-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102579-67-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1102579-72-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102579-73-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102581-02-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1102579-69-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102579-70-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102579-71-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102581-03-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.



HN 1102594-53-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102594-54-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.



13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RD 1102594-5-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RD 1102594-16-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RD 1102594-17-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RD 1102594-18-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RD 1102594-42-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RD 1102594-43-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RD 1102594-44-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RD 1102594-45-9 CAPLUS

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RD 1102594-59-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RD 1102594-60-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RD 1102594-61-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RD 1102594-66-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RD 1102594-67-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RD 1102594-68-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102594-69-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102594-70-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102594-71-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102594-72-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102594-73-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102594-74-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102594-75-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102594-76-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102594-77-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




HN 1102594-78-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102594-79-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.




HN 1102594-80-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.


L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



HN 1102595-41-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102595-42-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102595-40-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.

L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)


HN 1102595-44-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.



HN 1102595-45-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102595-46-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102595-46-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)




HN 1102595-41-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102595-42-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102595-43-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)



HN 1102595-67-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1102595-68-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.



HN 1102595-69-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RN 1102595-10-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102595-11-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RN 1102596-11-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.


13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RN 1102596-15-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102596-16-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.




RN 1102596-17-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RN 1102596-12-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102596-14-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RN 1102596-15-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.


13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RN 1102596-78-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RN 1102596-79-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RN 1102596-80-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




RN 1102596-01-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)




HN 1102594-82-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102594-83-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102594-84-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)




HN 1102594-88-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102594-89-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102594-90-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)




HN 1102594-85-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102594-86-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



HN 1102594-87-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STM (Continued)




HN 1102594-91-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




HN 1102594-92-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



HN 1102594-93-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


BN 1102597-15-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




BN 1102597-16-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



BN 1102597-17-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




BN 1102597-18-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


BN 1102597-22-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




BN 1102597-23-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




BN 1102597-24-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



BN 1102597-28-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


BN 1102597-19-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




BN 1102597-20-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



BN 1102597-21-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


BN 1102597-25-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




BN 1102597-26-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



BN 1102597-27-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




BN 1102597-28-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RD 1102597-13-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RD 1102597-13-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RD 1102597-11-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RD 1102597-12-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RD 1102597-13-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RD 1102597-14-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RD 1102597-15-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RD 1102597-16-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



RD 1102597-17-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.

13 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RD 1102597-18-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



RD 1102597-20-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.




RD 1102597-91-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.


L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1162599-67-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1162599-68-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1162599-69-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1162599-74-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1162599-75-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1162599-76-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.


L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1162599-70-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1162599-72-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.




HN 1162599-73-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.

L3 ANSWER 137 OF 143 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



HN 1162601-05-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE EE FORMAT

L3 ANSWER 142 OF 143 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)

13 ABSTRACT 143 OF 143 CARLOS COPYRIGHT 2009 ACS on STM
 ACCESSION NUMBER:
 1979:11743 CARLOS
 DOCUMENT NUMBER:
 3211743
 ORIGINAL REFERENCE NO.:
 251674a-b
 TITLE:
 o-Nitrochalcones
 AUTHOR(S):
 Taranovsky, L.; Baulin, A.
 SOURCE:
 Bulletin de la Societe Chimique de France, Memoires
 (1937), 6, 1740-55
 COUNTRY: RUSSIA; ISSN: 0368-3132

DOCUMENT TYPE:
 Journal
 LANGUAGE:
 Unavailable
 AB
 To study the effects of alkali, acid light reduction on this type of
 chalcone, a large number of o-nitro-substituted chalcones have been
 prepared

They contain the polymorphophoric group, Ph₂C=CH-C(=O), and can exist in
 several polymorphic forms. In general, the condensation of o-OMeC₆H₄CHO
 with various acetophenones was effected in alc. in the presence of alc.
 alkalis or HCl. A mixture of 3 g. o-OMeC₆H₄CHO and 2.4 g. AcPh in 20

cc. alc. was treated with 8 cc. of alc. NaOH (prepared from 1 cc. of 25% NaOH
 and 25 cc. of 95% alc.). The mixture was shaken and, on cooling,

crystallized out, giving an almost quant. yield of 2-nitrochalcone, m. 124°.
 Similarly were prepared the following 2-nitrochalcones: C15H10C1N3O3, m.

140°; 4'-bromo, C15H9BrO3, m. 137°; 4'-Me, C16H13NO3, m.
 111°; 3',4'-dimethyl, C17H17NO3, m. 124°; 2',4'-dimethyl
 (11a, m. 95°; 2',5'-dimethyl (12), m. 102°; 2'-nitro,
 C15H9N2O5, m. 152-53°; 4'-nitro, m. 77°; 4'-cyano,
 C16H10N2O3, m. 186-77°; 4'-oxymethyl, C16H13NO5, m. 245-6°
 Me ester, C17H15NO5, m. 173-44°; 2'-methyl, 4'-chloro, C16H12ClNO3,
 m. 117°; 3'-nitro-4'-Me, C16H12NO5, m. 136°;
 3'-nitro-4'-bromo, C16H9BrNO5, m. 202-3°; 4'-amino (111),
 C15H10N2O3, m. 178-87° (yellow unstable isomer of 121, m.
 82°); 4'-acetylamino (IV), C17H17NO4, m. 234° (blue isomer,
 m. 250-34°); 4'-benzoylamino, C18H17NO4, m. 182-3°;
 3'-acetylamino (V), m. 182° (phenylhydrazones, m. 98°);
 3'-nitro-4'-amino, C16H11NO5, green form, m. 243-4° (yellow
 isomer, m. 240-17°); 3',5'-di-bromo-4'-amino, C15H8Br2NO3, m.
 200-4° (4'-Methyl-α-acetophenone (1.6 g.) and 2 g.
 o-OMeC₆H₄CHO in 40 cc. of 95% alc. were saturated in the cold with HCl

and refluxed for 25 min. After the addition of 20 cc. concentrated HCl, the
 mixture was again refluxed for 30 min. A current of HCl was passed through as the
 solution was cooled down. Acrylate. of the crystalline product from 95%

alc. gave yellow needles of 2-nitro-4-methylbenzylidene-α-acetophenone,
 C16H13NO3, m. 121-22°. In the presence of NaOH the preparation of I
 and II led to polymorphic forms, m. 91.2° and 98°, resp.

The hydrolysis of IV with HCl gave a crystalline HCl salt, m. 207-10°,
 which, on boiling with 2.5% NaOH for 5 min., gave a red isomer of 121 as
 orange-red needles, m. 184°. 121 was converted into the


benzoylamine, C16H13NO3, m. 203-4°, and, on methylation with
 Me2SO4, gave a mixture of the 4'-dimethylamino and 4'-methylamino

derivs.
 C17H18NO3 and C16H14NO3, m. 110-11° and 153-4°, resp.

13 ABSTRACT 143 OF 143 CARLOS COPYRIGHT 2009 ACS on STM (Continued)
 Treatment of V with alc. HCl under reflux for 20 min. produced
 2-nitro-3'-aminochalcone-HCl, C15H12ClNO3, m. 195-9° (isomorph.),
 converted by boiling with 2.5% NaOH into 2-nitro-3'-aminochalcone,
 C15H12NO3, m. 142°. On boiling with dil. alc. alkali all the
 above chalcones gave red solids, which, in turn, yield indigo on the addn
 of a large excess of concd. HCl. This formation of indigo is favored by
 the presence of electropos. substituents. On solar irradiation, either in
 soln. or as a solid form, the chalcone undergo a profound transformation.
 Several chalcones have been obtained in 2 or more forms, due probably to
 stereoisomerism. The formation of these polychrome isomers is favored by
 the presence of electropos. substituents.

17 198779-28-7
 ELI STM (Synthetic preparation); FRF (Properties); FRF (Preparation)
 (o-Nitrochalcones)

18 198779-28-3 CARLOS
 CH Acetamide, N-[4-[1-(2-nitrophenyl)-1-oxo-2-propen-1-yl]phenyl]-,
 hydrochloride (111) [CA INDEX NAME]



10/562,112

=> d his

(FILE 'HOME' ENTERED AT 10:17:36 ON 02 APR 2009)

FILE 'REGISTRY' ENTERED AT 10:17:49 ON 02 APR 2009

L1 STRUCTURE UPLOADED

L2 19574 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:18:35 ON 02 APR 2009

L3 143 S L2 AND (BROMINATION OR CYANIDE OR CYANO)

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

XXXXXXXXXXXXXXXXXXXX

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-117.26	-117.26
---------	---------

STN INTERNATIONAL LOGOFF AT 10:20:56 ON 02 APR 2009